



11-13-00

A

Attorney Docket No.: 5563.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Express Mail Label No. EL285641612US

Date of Deposit: November 10, 2000

Sir:

This is a request for filing a **Divisional** application under 37 C.F.R.  
1.53(b) of

**Applicant(s): Royer et al.**

**Title: Methods for Producing Heterologous Polypeptides In  
Trichothecene-Deficient Filamentous Fungal Mutant Cells**

74 pages of specification 16 sheets of formal drawings


8 pages of Sequence Listing 3 sheets of Declaration and Power of Attorney

**[x] The filing fee is calculated as follows:**

Basic Fee:	\$710.00
Total Claims: 0 - 20 = 0 x 18 =	\$0
Independent Claims: 0 - 3 = 0 x 80 =	\$0
Total Fee:	\$710.00

This application is a divisional of U.S. application Serial No. **09/316,080** filed on **May 20, 1999** and claims priority from U.S. application Serial No. **09/082,217**, filed on **May 20, 1998**, now abandoned, which applications are fully incorporated herein by reference.

Address all future communications to Robert L. Starnes, Novo Nordisk Biotech, Inc., 1445 Drew Avenue, Davis, CA 95616.



09/10760-144000

[illegible]

Respectfully submitted,  
Nobut L. Name

Robert L. Starnes, Reg. No. 41,324  
Novo Nordisk Biotech, Inc.  
1445 Drew Avenue  
Davis, CA 95616  
(530) 757-8100

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
EXPRESS MAIL CERTIFICATE**

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Re: U.S. Patent Application for  
"Methods For Producing Heterologous Polypeptides In  
Trichothecene-Deficient Filamentous Fungal Mutant Cells"  
Applicants: Royer *et al.*

Sir:

Express Mail Label No.: EL285641612US

Date of Deposit: November 10, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Request Transfer of Computer Readable Sequence Listing
6. Verified Statement
7. Information Disclosure Statement
8. PTO-1449
9. 16 Sheets of Drawings

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Seleste A. Buriani

(Name of person mailing papers or fees)

Seleste A. Buriani

(Signature of person mailing papers or fees)

Mailing Address:  
Novo Nordisk Biotech, Inc.  
1445 Drew Avenue  
Davis, CA 95616  
(530) 757-8100

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Royer *et al.*

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: November 10, 2000

Examiner: To Be Assigned

For: Methods For Producing Heterologous Polypeptides In Trichothecene-Deficient  
Filamentous Fungal Mutant Cells

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the  
following amendment is respectfully requested:

**IN THE SPECIFICATION**

At page 1, amend lines 9-11 to read as follows:

-- This application is a divisional of pending U.S. application Serial No.  
09/316,080 filed May 20, 1999, which claims priority from U.S. application Serial No.  
09/082,217 filed on May 20, 1998, now abandoned, which applications are fully  
incorporated herein by reference.--

**IN THE CLAIMS**

Please cancel claims 1-69 without prejudice or disclaimer. Please add new  
claims 70-76 as follows:

70. An isolated trichodiene synthase obtained from a *Fusarium venenatum* strain, selected from the group consisting of:

- (a) a trichodiene synthase having an amino acid sequence which has at least 97% identity with SEQ ID NO. 2;
- (b) a variant of the trichodiene synthase having an amino acid sequence of SEQ ID NO. 2 comprising a substitution, deletion, and/or insertion of one or more amino acids;
- (c) an allelic variant of (a) or (b); and
- (d) a fragment of (a) or (c) that has trichodiene synthase activity.

71. The trichodiene synthase of claim 70, having an amino acid sequence which has at least 97% identity with SEQ ID NO. 2.

72. The trichodiene synthase of claim 70, comprising the amino acid sequence of SEQ ID NO. 2 or a fragment thereof having trichodiene synthase activity.

73. The trichodiene synthase of claim 72, comprising the amino acid sequence of SEQ ID NO. 2.

74. The trichodiene synthase of claim 70, which is a variant of the trichodiene synthase having an amino acid sequence of SEQ ID NO:2 comprising a substitution, deletion, and/or insertion of one or more amino acids.

75. The trichodiene synthase of claim 70, which is obtained from *Fusarium venenatum* ATCC 20334.

76. The trichodiene synthase of claim 70, which is encoded by the nucleic acid sequence contained in plasmid pTri5 contained in *E. coli* NRRL B-30029.

#### REMARKS

The present application is a continuation of U.S. application Serial No.

09/316,080 filed May 20, 1999, which claims priority from U.S. application Serial No. 09/082,217 filed on May 20, 1998, now abandoned. Claims 1-69 have been cancelled and new claims 70-76 added.

Respectfully submitted,

Date: November 10, 2000

Robert L. Barnes

Robert L. Starnes, Reg. No. 41,324  
Novo Nordisk Biotech, Inc.  
1445 Drew Avenue  
Davis, CA 95616-4880  
(530) 757-8100

[illegible]

**METHODS FOR PRODUCING HETEROLOGOUS POLYPEPTIDES  
IN TRICHOTHECENE-DEFICIENT  
FILAMENTOUS FUNGAL MUTANT CELLS**

**Cross-Reference to Related Application**

This application is a continuation-in-part of pending U.S. application Serial No. 09/082,217 filed on May 20, 1998, which application is fully incorporated herein by reference.

**Background of the Invention**

**Field of the Invention**

The present invention relates to methods for producing heterologous polypeptides in trichothecene-deficient filamentous fungal mutant cells. The present invention also relates to such mutant cells of filamentous fungal cells and methods for obtaining the mutant cells. The present invention also relates to isolated trichodiene synthases and isolated nucleic acid sequences encoding the trichodiene synthases. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the trichodiene synthases. The present invention further relates to mutants cells comprising a marker-free modification of a gene, and methods for obtaining and using such mutant cells.

**Description of the Related Art**

Trichothecenes are sesquiterpene epoxides which are named after the fungus *Trichothecium roseum* from which the first trichothecene was isolated. The trichothecenes T-2 toxin, diacetoxyscirpenol, and deoxynivalenol are most commonly found in agricultural commodities infected with *Fusarium* species. Interest in these compounds is due primarily to the discovery that trichothecene contamination of foods and feeds may be detrimental in humans and animals.

Trichothecenes are produced by a sequence of oxygenations, isomerizations, cyclizations, and esterifications leading from trichodiene, which is produced from the cyclization of *trans, trans*-farnesyl pyrophosphate by the enzyme trichodiene synthase (Desjardins, Hohn, and McCormick, 1993, *Microbiological Reviews* 57: 595-604).

5 The trichodiene synthase gene (*tri5* or *tox5*) has been cloned from *Fusarium sporotrichioides* (Hohn and Beremand, 1989, *Gene* 79: 131-138); *Gibberella pulicaris* (Hohn and Desjardins, 1992, *Molecular Plant-Microbe Interactions* 5: 249-256); *Gibberella zeae* (Proctor *et al.*, 1995, *Molecular Plant-Microbe Interactions* 4: 593-601); *Myrothecium roridin* (Trapp, *et al.*, 1995, *Journal of Cellular Biochemistry Supplement* 19B: 154); and  
10 *Fusarium poae* (Fekete *et al.*, 1997, *Mycopathologia* 138: 91-97).

*Tri5*<sup>-</sup> mutants of *Gibberella pulicaris* (Hohn and Desjardins, 1992, *supra*) and *Gibberella zeae* (Proctor *et al.*, 1995, *supra*) have been generated which do not produce trichothecenes.

Other genes in the trichothecene biosynthetic pathway have been cloned including the  
15 *tri3* gene, encoding a 15-O-acetyltransferase, from *Fusarium sporotrichioides* (McCormick *et al.*, 1996, *Applied and Environmental Microbiology* 62: 353-359); the *tri4* gene, encoding a cytochrome P450 monooxygenase, from *Fusarium sporotrichioides* (Hohn *et al.*, 1995, *Molecular and General Genetics* 248: 95-102); the *tri6* gene, encoding a zinc finger protein involved in the regulation of trichothecene biosynthesis, from *Fusarium sporotrichioides*  
20 (Proctor *et al.*, 1995, *Applied and Environmental Microbiology* 61: 1923-1930); the *tri11* gene, encoding a cytochrome P450 monooxygenase required for C-15 hydroxylation, from *Fusarium sporotrichioides* (Alexander *et al.*, 1997, *Applied and Environmental Microbiology* 64: 221-225); the *tri12* gene, which encodes an apparent transport protein involved in trichothecene production, from *Fusarium sporotrichioides* (Alexander *et al.*, 1997, *Cereal*  
25 *Research Communications* 25: 347-348); and the *tri101* gene, encoding a 3-O-acetyltransferase, from *Fusarium graminearum* (Kimura *et al.*, 1998, *Journal of Biological Chemistry* 272: 1654-1661).

It is an object of the present invention to provide methods for producing polypeptides in mutant cells.



## Summary of the Invention

The present invention relates to methods for producing a heterologous polypeptide, comprising: (a) cultivating a mutant cell of a parent filamentous fungal cell under conditions conducive for the production of the heterologous polypeptide, wherein (i) the mutant cell comprises a first nucleic acid sequence encoding the heterologous polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a trichothecene and (ii) the mutant cell produces less of the trichothecene than the parent filamentous fungal cell when cultured under the same conditions; and (b) isolating the heterologous polypeptide from the cultivation medium. The present invention also relates to mutant cells of filamentous fungal cells and methods for obtaining the mutant cells.

The present invention also relates to isolated trichodiene synthases and isolated nucleic acid sequences encoding the trichodiene synthases. The invention further relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the trichodiene synthases.

The present invention also relates to methods for obtaining a mutant cell, comprising: (a) introducing into a parent cell, having a first nucleic acid sequence encoding a first polypeptide, a first nucleic acid construct comprising a nitrate reductase gene as a selectable marker and a modification of the first nucleic acid sequence, wherein the first construct incorporates into the genome of the parent cell replacing the endogenous first nucleic acid sequence with the modified first nucleic acid sequence resulting in reduced production of the first polypeptide compared to the parent cell when cultivated under the same conditions; and (b) selecting a mutant cell from step (a) for the presence of the nitrate reductase gene and reduced production of the first polypeptide.

In a preferred embodiment, the methods for obtaining a mutant cell may further comprise (c) selecting a mutant cell from step (b) under culturing conditions in which the nitrate reductase gene is deleted. In another preferred embodiment, the methods for obtaining a mutant cell may further comprise (c) introducing into the mutant cell from step (b) a second nucleic acid construct comprising a second nucleic acid sequence comprising 5' and 3' regions of the modified first nucleic acid sequence, but lacking the nitrate reductase gene, wherein the second construct incorporates into the genome of the parent cell replacing the

modified first nucleic acid sequence with the second nucleic acid sequence; and (d) selecting a mutant cell from step (c) under culturing conditions in which the nitrate reductase gene is deleted.

The present invention further relates to mutant cells obtained from such methods and methods for producing polypeptides with such mutant cells.

### Brief Description of Figures

Figure 1 shows the trichothecene biosynthetic pathway in *Fusarium* species.

Figures 2A-2E shows the genomic nucleic acid sequence and the deduced amino acid sequence of a *Fusarium venenatum* ATCC 20334 trichodiene synthase (SEQ ID NOS. 1 and 2, respectively).

Figure 3 shows a restriction map of pDM181.

Figure 4 shows a restriction map of pJRoy36.

Figure 5 shows a restriction map of pJRoy40.

Figure 6 shows a restriction map of pBANE20.

Figure 7 shows a restriction map of pLC30.

Figure 8 shows the construction of pJRoy41.

Figure 9 shows the protocol for deletion of the *tri5* gene and removal of the *amdS* selectable marker.

Figure 10 shows a restriction map of pJRoy44.

Figure 11 shows a restriction map of pJRoy47.

Figure 12 shows the construction of pLC31b.

### Detailed Description of the Invention

#### Trichothecene-Deficient Mutant Cells

The present invention relates to methods for producing a heterologous polypeptide, comprising: (a) cultivating a mutant cell of a parent filamentous fungal cell under conditions conducive for the production of the heterologous polypeptide, wherein (i) the mutant cell relates to the parent cell by a modification, e.g., disruption or deletion, of one or more genes

involved in the production of a trichothecene and (ii) the mutant cell produces less of the trichothecene than the parent cell when cultured under the same conditions; and (b) isolating the heterologous polypeptide from the cultivation medium of the mutant cell.

The term "trichothecenes" is defined herein as a family of sesquiterpene epoxides produced by a sequence of oxygenations, isomerizations, cyclizations, and esterifications leading from trichodiene to the more complex trichothecenes. The trichothecenes include, but are not limited to, 2-hydroxytrichodiene, 12,13-epoxy-9,10-trichoene-2-ol, isotrichodiol, isotrichotriol, trichotriol, isotrichodermol, isotrichodermin, 15-decalonectrin, 3,15-didecalonectrin, deoxynivalenol, 3-acetyldeoxynivalenol, calonectrin, 3,15-diacetoxyscirpenol, 3,4,15-triacetoxyscirpenol, 4,15-diacetoxyscirpenol, 3-acetylneosolaniol, acetyl T-2 toxin, and T-2 toxin; and derivatives thereof. The trichothecene biosynthetic pathway is shown in Figure 1 (Desjardins, Hohn, and McCormick, 1993, *supra*).

The term "production of a trichothecene" is defined herein to include any step involved in the production of a trichothecene including, but not limited to, biosynthesis, regulation of biosynthesis, transport, and secretion.

In the methods of the present invention, the filamentous fungal cell may be a wild-type cell or a mutant thereof. Furthermore, the filamentous fungal cell may be a cell which does not produce any detectable trichothecene(s), but contains the genes encoding a trichothecene(s). Preferably, the filamentous fungal cell is an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Gibberella*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Myrothecium*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, or *Trichoderma* cell.

In a preferred embodiment, the filamentous fungal cell is an *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, or *Aspergillus oryzae* cell.

In another preferred embodiment, the filamentous fungal cell is a *Fusarium bactridioides*, *Fusarium crookwellense* (synonym of *Fusarium cerealis*), *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium solani*, *Fusarium sporotrichioides*,

*Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, or *Fusarium venenatum* cell.

In another preferred embodiment, the filamentous fungal cell is a *Gibberella pulicaris*, *Gibberella zeae*, *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*,  
5 *Myceliophthora thermophila*, *Myrothecium roridin*, *Neurospora crassa*, or *Penicillium purpurogenum* cell.

In another preferred embodiment, the filamentous fungal cell is a *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* cell.

10 In a more preferred embodiment, the *Fusarium venenatum* cell is *Fusarium venenatum* A3/5, which was originally deposited as *Fusarium graminearum* ATCC 20334 and recently reclassified as *Fusarium venenatum* by Yoder and Christianson, 1998, *Fungal Genetics and Biology* 23: 62-80 and O'Donnell *et al.*, 1998, *Fungal Genetics and Biology* 23: 57-67; as well as taxonomic equivalents of *Fusarium venenatum* regardless of the species  
15 name by which they are currently known. In another preferred embodiment, the *Fusarium venenatum* cell is a morphological mutant of *Fusarium venenatum* A3/5 or *Fusarium venenatum* ATCC 20334, as disclosed in WO 97/26330.

In the methods of the present invention, any gene of a filamentous fungal cell involved in the production of a trichothecene may be modified including, but not limited to,  
20 *tri3*, *tri4*, *tri5*, *tri6*, *tri11*, *tri12*, and/or *tri101*. In a preferred embodiment, the gene is *tri5*. In a more preferred embodiment, the gene is the *Fusarium venenatum tri5* gene having the nucleic acid sequence of SEQ ID NO. 1.

The trichothecene-deficient filamentous fungal mutant cell may be constructed by reducing or eliminating expression of one or more of the genes described herein using  
25 methods well known in the art, for example, insertions, disruptions, replacements, or deletions. The gene to be modified or inactivated may be, for example, the coding region or a part thereof essential for activity, or the gene may contain a regulatory element required for expression of the coding region. An example of such a regulatory or control sequence may be a promoter sequence or a functional part thereof, *i.e.*, a part which is sufficient for  
30 affecting expression of the nucleic acid sequence. Other control sequences for possible modification include, but are not limited to, a leader, polyadenylation sequence, propeptide

sequence, signal sequence, transcription terminator, and transcriptional activator.

Modification or inactivation of the gene may be performed by subjecting the parent cell to mutagenesis and screening for mutant cells in which expression of the gene has been reduced or eliminated. The mutagenesis, which may be specific or random, may be performed, for example, by use of a suitable physical or chemical mutagenizing agent, use of a suitable oligonucleotide, or subjecting the DNA sequence to PCR generated mutagenesis. Furthermore, the mutagenesis may be performed by use of any combination of these mutagenizing methods.

Examples of a physical or chemical mutagenizing agent suitable for the present purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues.

When such agents are used, the mutagenesis is typically performed by incubating the parent cell to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions, and selecting for mutant cells exhibiting reduced or no expression of the gene.

Modification or inactivation of the gene may be also accomplished by introduction, substitution, or removal of one or more nucleotides in the gene or a regulatory element required for the transcription or translation thereof. For example, nucleotides may be inserted or removed so as to result in the introduction of a stop codon, the removal of the start codon, or a change of the open reading frame. Such a modification or inactivation may be accomplished by site-directed mutagenesis or PCR generated mutagenesis in accordance with methods known in the art. Although, in principle, the modification may be performed *in vivo*, i.e., directly on the cell expressing the gene to be modified, it is preferred that the modification be performed *in vitro* as exemplified below.

An example of a convenient way to inactivate or reduce production of a trichothecene by a filamentous fungal cell of choice is based on techniques of gene replacement, gene deletion, or gene disruption. For example, in the gene disruption method, a nucleic acid sequence corresponding to the endogenous gene or gene fragment of interest is mutagenized *in vitro* to produce a defective nucleic acid sequence which is then transformed into the parent cell to produce a defective gene. By homologous recombination, the defective nucleic

acid sequence replaces the endogenous gene or gene fragment. It may be desirable that the defective gene or gene fragment also encodes a marker which may be used for selection of transformants in which the nucleic acid sequence has been modified or destroyed. The selectable marker gene may be used to achieve the disruption. The defective nucleic acid sequence may be a simple disruption of the endogenous sequence with a selectable marker gene. Alternatively, the defective nucleic acid sequence may contain an insertion or deletion of the endogenous sequence, or a portion thereof, in addition to the disruption with the selectable marker gene. Furthermore, the defective nucleic acid sequence may contain an insertion or deletion of the endogenous sequence, or a portion thereof, and the selectable marker gene is not involved in the modification but is used as a selectable marker for identifying transformants containing the defective gene.

Alternatively, modification or inactivation of the gene may be performed by established anti-sense techniques using a nucleotide sequence complementary to the nucleic acid sequence of the gene. More specifically, expression of the gene by a filamentous fungal cell may be reduced or eliminated by introducing a nucleotide sequence complementary to the nucleic acid sequence of the gene which may be transcribed in the cell and is capable of hybridizing to the mRNA produced in the cell. Under conditions allowing the complementary anti-sense nucleotide sequence to hybridize to the mRNA, the amount of protein translated is thus reduced or eliminated.

A nucleic acid sequence homologous or complementary to the nucleic acid sequence of a gene involved in the production of a trichothecene in a filamentous fungal cell may be obtained from other microbial sources which produce trichothecenes. Preferred sources for a *tri5* gene having a nucleic acid sequence complementary or homologous to the nucleic acid sequence of SEQ ID NO. 1 of *Fusarium venenatum* include, but are not limited to, *Fusarium sporotrichioides* (Hohn and Beremand, 1989, *supra*); *Gibberella pulicaris* (Hohn and Desjardins, 1992, *supra*); *Gibberella zeae* (Proctor *et al.*, 1995, *supra*); *Myrothecium roridin* (Trapp *et al.*, 1995, *supra*); and *Fusarium poae* (Fekete *et al.*, 1997, *supra*).

Preferred sources for other genes in the trichothecene biosynthetic pathway which may be complementary or homologous to the nucleic acid sequence of the corresponding genes of a filamentous fungal cell include, but are not limited to, the *tri3* gene from *Fusarium sporotrichioides* (McCormick *et al.*, 1996, *supra*); the *tri4* gene from *Fusarium*

*sporotrichioides* (Hohn *et al.*, 1995, *supra*); the *tri6* gene from *Fusarium sporotrichioides* (Proctor *et al.*, 1995, *supra*); the *tril1* gene from *Fusarium sporotrichioides* (Alexander *et al.*, 1997, *supra*); the *tril2* gene from *Fusarium sporotrichioides* (Alexander *et al.*, 1997, *supra*); and the *tri101* gene from *Fusarium graminearum* (Kimura *et al.*, 1998, *supra*).

5 Furthermore, the nucleic acid sequences may be native to the filamentous fungal cell.

In a preferred embodiment, the modification of a gene involved in the production of a trichothecene in the mutant filamentous fungal cell is unmarked with a selectable marker.

Removal of the selectable marker gene may be selected for by culturing the mutants on a counter-selection medium. Where the selectable marker gene contains repeats flanking  
10 its 5' and 3' ends, the repeats will facilitate the looping out of the selectable marker gene by homologous recombination when the mutant cell is submitted to counter-selection. The selectable marker gene may also be removed by homologous recombination by introducing into the mutant cell a nucleic acid fragment comprising 5' and 3' regions of the defective  
15 gene, but lacking the selectable marker gene, followed by selecting on the counter-selection medium. By homologous recombination, the defective gene containing the selectable marker gene is replaced with the nucleic acid fragment lacking the selectable marker gene. Other methods known in the art may also be used.

It will be understood that the methods of the present invention are not limited to a particular order for obtaining the mutant filamentous fungal cell. The modification of the  
20 gene involved in the production of a trichothecene may be introduced into the parent cell at any step in the construction of the cell for the production of a heterologous polypeptide. It is preferable that the filamentous fungal mutant has already been made trichothecene-deficient prior to the introduction of a gene encoding a heterologous polypeptide.

The level of trichothecenes produced by a mutant filamentous fungal cell of the  
25 present invention may be determined using methods well known in the art (see, for example, Rood *et al.*, 1988, *Journal of Agricultural and Food Chemistry* 36:74-79; Romer, 1986, *Journal of the Association of Official Analytical Chemists* 69: 699-703; McCormick *et al.*, 1990, *Applied and Environmental Microbiology* 56: 702-706). The mutant filamentous fungal cell preferably produces at least about 25% less, more preferably at least about 50%  
30 less, even more preferably at least about 75% less, most preferably at least about 95% less, and even most preferably no trichothecene compared to the corresponding parent filamentous

fungal cell when cultured under identical conditions. The parent and mutant cells may be compared with regard to production of a trichothecene under conditions conducive for the production of a polypeptide of interest or under conditions conducive for the production of a trichothecene.

5       The mutant filamentous fungal cell is cultivated in a nutrient medium suitable for production of a heterologous polypeptide of interest using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, or small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors with a suitable medium and under conditions allowing the  
10 heterologous polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (*e.g.*, in catalogues of the American Type Culture Collection). The heterologous polypeptide can be recovered directly from the  
15 medium if secreted.

20       The heterologous polypeptide may be detected using methods known in the art that are specific for the polypeptide. These detection methods may include use of specific antibodies, formation of an enzyme product, disappearance of an enzyme substrate, SDS-PAGE, or any other method known in the art. For example, an enzyme assay may be used to determine the activity of the heterologous polypeptide. Procedures for determining enzyme activity are known in the art for many enzymes.

25       The resulting heterologous polypeptide may be isolated by methods known in the art. For example, the polypeptide may be isolated from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. The isolated polypeptide may then be further purified by a  
30 variety of procedures known in the art including, but not limited to, chromatography (*e.g.*, ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (*e.g.*, preparative isoelectric focusing), differential solubility (*e.g.*, ammonium sulfate precipitation), or extraction (see, *e.g.*, *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

The polypeptide may be any polypeptide heterologous to the mutant filamentous



5 fungal cell. The term "polypeptide" is not meant herein to refer to a specific length of the encoded product and, therefore, encompasses peptides, oligopeptides, and proteins. The term "heterologous polypeptide" is defined herein as a polypeptide which is not native to the filamentous fungal cell. The mutant filamentous fungal cell may contain one or more copies of the nucleic acid sequence encoding the heterologous polypeptide.

10 In a preferred embodiment, the heterologous polypeptide is a hormone, hormone variant, enzyme, receptor or portion thereof, antibody or portion thereof, or reporter. In a more preferred embodiment, the heterologous polypeptide is an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase. In an even more preferred embodiment, the heterologous polypeptide is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase or xylanase.

15 In the methods of the present invention, the heterologous polypeptide may also be an engineered variant of a polypeptide.

20 The nucleic acid sequence encoding a heterologous polypeptide which can be expressed in a filamentous fungal cell may be obtained from any prokaryotic, eukaryotic, or other source. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the polypeptide is produced by the source or by a cell in which a gene from the source has been inserted.

25 In the methods of the present invention, the mutant filamentous fungal cell may also be used for the recombinant production of polypeptides which are native to the cell. The native polypeptides may be recombinantly produced by, for example, placing a gene encoding the polypeptide under the control of a different promoter to enhance expression of the polypeptide, to expedite export of a native polypeptide of interest outside the cell by use of a signal sequence, and to increase the copy number of a gene encoding the polypeptide normally produced by the cell. The present invention also encompasses, within the scope of the term "heterologous polypeptide", such recombinant production of endogenous polypeptides native to the filamentous fungal cell, to the extent that such expression involves

the use of genetic elements not native to the cell, or use of native elements which have been manipulated to function in a manner that do not normally occur in the host cell.

The techniques used to isolate or clone a nucleic acid sequence encoding a heterologous polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequence from such genomic DNA can be effected, *e.g.*, by using the well known polymerase chain reaction (PCR). See, for example, Innis *et al.*, 1990, *PCR Protocols: A Guide to Methods and Application*, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into the mutant fungal cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

In the methods of the present invention, heterologous polypeptides may also include fused or hybrid polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding one polypeptide to a nucleic acid sequence (or a portion thereof) encoding another polypeptide. Techniques for producing fusion polypeptides are known in the art, and include, ligating the coding sequences encoding the polypeptides so that they are in frame and expression of the fused polypeptide is under control of the same promoter(s) and terminator. The hybrid polypeptides may comprise a combination of partial or complete polypeptide sequences obtained from at least two different polypeptides wherein one or more may be heterologous to the mutant filamentous fungal cell.

An isolated nucleic acid sequence encoding a heterologous polypeptide of interest may be manipulated in a variety of ways to provide for expression of the polypeptide. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Manipulation of the nucleic acid sequence prior to its insertion into a vector may be desirable or necessary depending on the

expression vector. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence. The term "coding sequence" as defined herein is a sequence which is transcribed into mRNA and translated into a polypeptide. The boundaries of the genomic coding sequence are generally determined by the ATG start codon located just upstream of the open reading frame at the 5' end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3' end of the mRNA. A coding sequence can include, but is not limited to, genomic, cDNA, RNA, semisynthetic, synthetic, recombinant, or any combinations thereof.

The term "control sequences" is defined herein to include all components which are necessary or advantageous for the expression of a heterologous polypeptide. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a heterologous polypeptide. The term "operably linked" is defined herein as a configuration in which a control sequence is appropriately placed at a position relative to the coding sequence of the DNA sequence such that the control sequence directs the production of a heterologous polypeptide.

The control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a filamentous fungal cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences which mediate the expression of the heterologous polypeptide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the filamentous fungal cell including

mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the cell.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs in the methods of the present invention are promoters obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Aspergillus oryzae* acetamidase, *Fusarium oxysporum* trypsin-like protease (U.S. Patent No. 4,288,627), and mutant, truncated, and hybrid promoters thereof. Particularly preferred promoters are the glucoamylase, TAKA amylase, and NA2-tpi promoters (a hybrid of the promoters from the genes encoding *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase).

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a filamentous fungal cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the heterologous polypeptide. Any terminator which is functional in the filamentous fungal cell may be used in the present invention.

Preferred terminators are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* alpha-glucosidase, and *Fusarium oxysporum* trypsin-like protease.

The control sequence may also be a suitable leader sequence, a nontranslated region of a mRNA which is important for translation by the filamentous fungal cell. The leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the heterologous polypeptide. Any leader sequence which is functional in the filamentous fungal cell may be used in the present invention.

Preferred leaders are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase and *Aspergillus nidulans* triose phosphate isomerase.

The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by a filamentous fungal cell as a signal to add polyadenosine residues to

transcribed mRNA. Any polyadenylation sequence which is functional in the filamentous fungal cell may be used in the present invention.

Preferred polyadenylation sequences are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, and *Aspergillus niger* alpha-glucosidase.

The control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of the heterologous polypeptide and directs the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the polypeptide. However, any signal peptide coding region which directs the expressed heterologous polypeptide into the secretory pathway of a filamentous fungal cell may be used in the present invention.

Effective signal peptide coding regions for filamentous fungal host cells are the signal peptide coding regions obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* neutral amylase, *Aspergillus niger* glucoamylase, *Rhizomucor miehei* aspartic proteinase, *Humicola insolens* cellulase, and *Humicola lanuginosa* lipase.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature, active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Rhizomucor miehei* aspartic proteinase gene, or the *Myceliophthora thermophila* laccase gene (WO 95/33836).

Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of a

polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

The nucleic acid constructs may also comprise one or more nucleic acid sequences which encode one or more factors that are advantageous for directing the expression of the heterologous polypeptide, *e.g.*, a transcriptional activator (*e.g.*, a *trans*-acting factor), a chaperone, and a processing protease. Any factor that is functional in a filamentous fungal cell may be used in the present invention. The nucleic acids encoding one or more of these factors are not necessarily in tandem with the nucleic acid sequence encoding the heterologous polypeptide.

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the heterologous polypeptide relative to the growth of the filamentous fungal cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. The TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification, *e.g.*, the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the heterologous polypeptide would be operably linked with the regulatory sequence.

The expression of a nucleic acid sequence which is endogenous to a cell may also be altered using a nucleic acid construct containing the minimal number of components necessary for altering expression of the endogenous nucleic acid sequence. In one embodiment, the nucleic acid constructs preferably contain (a) a targeting sequence, (b) a regulatory sequence, (c) an exon, and (d) a splice-donor site. Upon introduction of the nucleic acid construct into a cell, the construct inserts by homologous recombination into the cellular genome at the endogenous nucleic acid sequence site. The targeting sequence directs the integration of elements (a)-(d) into the endogenous nucleic acid sequence such that elements (b)-(d) are operably linked to the endogenous nucleic acid sequence. In another embodiment, the nucleic acid constructs contain (a) a targeting sequence, (b) a regulatory sequence, (c) an exon, (d) a splice-donor site, (e) an intron, and (f) a splice-acceptor site, wherein the targeting sequence directs the integration of elements (a)-(f) such that elements

(b)-(f) are operably linked to the endogenous nucleic acid sequence. However, the constructs may contain additional components such as a selectable marker.

In both embodiments, the introduction of these components results in production of a new transcription unit in which expression of the endogenous nucleic acid sequence is altered. In essence, the new transcription unit is a fusion product of the sequences introduced by the targeting constructs and the endogenous nucleic acid sequence. In one embodiment, in which the endogenous nucleic acid sequence is altered, the nucleic acid sequence is activated.

In this embodiment, homologous recombination is used to replace, disrupt, or disable the regulatory region normally associated with the endogenous nucleic acid sequence of a parent cell through the insertion of a regulatory sequence which causes the nucleic acid sequence to be expressed at higher levels than evident in the corresponding parent cell. The activated nucleic acid sequence can be further amplified by the inclusion of an amplifiable selectable marker gene in the construct using methods well known in the art (see, for example, U.S. Patent No. 5,641,670). In another embodiment, in which the endogenous nucleic acid sequence is altered, expression of the gene is reduced.

The targeting sequence can be within the endogenous nucleic acid sequence, immediately adjacent to the nucleic acid sequence, within an upstream gene, or upstream of and at a distance from the endogenous nucleic acid sequence. One or more targeting sequences can be used. For example, a circular plasmid or DNA fragment thereof preferably employs a single targeting sequence, while a linear plasmid or DNA fragment thereof preferably employs two targeting sequences.

The regulatory sequence of the construct can be comprised of one or more promoters, enhancers, scaffold-attachment regions or matrix attachment sites, negative regulatory elements, transcription binding sites, or combinations of these sequences.

The constructs further contain one or more exons of the endogenous nucleic acid sequence. An exon is defined as a DNA sequence which is copied into RNA and is present in a mature mRNA molecule such that the exon sequence is in-frame with the coding region of the endogenous nucleic acid sequence. The exons can, optionally, contain DNA which encodes one or more amino acids and/or partially encodes an amino acid. Alternatively, the exon contains DNA which corresponds to a 5' non-encoding region. Where the exogenous exon or exons encode one or more amino acids and/or a portion of an amino acid, the nucleic

acid construct is designed such that, upon transcription and splicing, the reading frame is in-frame with the coding region of the endogenous nucleic acid sequence so that the appropriate reading frame of the portion of the mRNA derived from the second exon is unchanged.

5 The splice-donor site of the constructs directs the splicing of one exon to another exon. Typically, the first exon lies 5' of the second exon, and the splice-donor site overlapping and flanking the first exon on its 3' side recognizes a splice-acceptor site flanking the second exon on the 5' side of the second exon. A splice-acceptor site, like a splice-donor site, is a sequence which directs the splicing of one exon to another exon. Acting in conjunction with a splice-donor site, the splicing apparatus uses a splice-acceptor  
10 site to effect the removal of an intron.

The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the heterologous polypeptide at such sites. Alternatively, the nucleic acid sequence  
15 encoding the heterologous polypeptide may be expressed by inserting the sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.

20 The recombinant expression vector may be any vector (*e.g.*, a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence encoding the heterologous polypeptide. The choice of the vector will typically depend on the compatibility of the vector with the filamentous fungal cell into which the vector is to be introduced. The vectors may be linear or closed  
25 circular plasmids. The vector may be an autonomously replicating vector, *i.e.*, a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *e.g.*, a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the filamentous fungal  
30 cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more



vectors or plasmids which together contain the total DNA to be introduced into the genome of the filamentous fungal cell, or a transposon.

The vectors preferably contain one or more selectable markers which permit easy selection of transformed filamentous fungal cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. A selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hph* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), and *trpC* (anthranilate synthase), as well as equivalents from other species. Preferred for use in a filamentous fungal cell are the *amdS* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygroscopicus*.

The vectors preferably contain an element(s) that permits stable integration of the vector into a filamentous fungal cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

"Introduction" means introducing a vector comprising the nucleic acid sequence into a filamentous fungal cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the vector into the chromosome occurs by homologous recombination, non-homologous recombination, or transposition.

The introduction of an expression vector into a filamentous fungal cell may involve a process consisting of protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* host cells are described in EP 238 023 and Yelton *et al.*, 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474. Suitable methods of transforming *Fusarium* species are described by Malardier *et al.*, 1989, *Gene* 78: 147-156, and WO 96/00787.

For integration into the genome of a filamentous fungal cell, the vector may rely on the nucleic acid sequence encoding the heterologous polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous

recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the filamentous fungal cell. The additional nucleic acid sequences enable the vector to be integrated into the genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequences that are homologous with the target sequence in the genome of the filamentous fungal cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the filamentous fungal cell in question.

The procedures used to ligate the elements described herein to construct the recombinant expression vectors are well known to one skilled in the art (see, e.g., J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York).

In another aspect of the present invention, the mutant filamentous fungal cell may additionally contain modifications of one or more nucleic acid sequences which encode proteins that may be detrimental to the production, recovery, and/or application of the heterologous polypeptide of interest. The modification reduces or eliminates expression of the one or more third nucleic acid sequences resulting in a mutant cell which may produce more of the heterologous polypeptide than the mutant cell without the modification of the third nucleic acid sequence when cultured under the same conditions.

The third nucleic acid sequence may encode any protein or enzyme. For example, the enzyme may be an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease,

transglutaminase, or xylanase. The third nucleic acid sequence preferably encodes a proteolytic enzyme, *e.g.*, an aminopeptidase, carboxypeptidase, or protease.

The present invention also relates to methods for obtaining a trichothecene-deficient filamentous fungal mutant cell which comprise (a) introducing into a parent filamentous fungal cell a nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a trichothecene; and (b) identifying the mutant from step (a) comprising the modified nucleic acid sequence, wherein the mutant cell produces less of the trichothecene than the parent filamentous fungal cell of the mutant cell when cultured under the same conditions.

The present invention also relates to trichothecene-deficient mutants of filamentous fungal cells for producing a heterologous polypeptide which comprise a first nucleic acid sequence encoding the heterologous polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a trichothecene, wherein the mutant cell produces less of the trichothecene than the parent filamentous fungal cell of the mutant cell when cultured under the same conditions.

#### **Trichodiene Synthases and Nucleic Acids Encoding Same**

The present invention also relates to isolated trichodiene synthases.

In a first embodiment, the present invention relates to isolated trichodiene synthases having an amino acid sequence which has a degree of identity to SEQ ID NO. 2 of at least about 97% (hereinafter "homologous polypeptides"). In a preferred embodiment, the homologous polypeptides have an amino acid sequence which differs by five amino acids, preferably by four amino acids, more preferably by three amino acids, even more preferably by two amino acids, and most preferably by one amino acid from SEQ ID NO. 2. For purposes of the present invention, the degree of identity between two amino acid sequences is determined by the Clustal method (Higgins, 1989, *CABIOS* 5: 151-153) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10 and gap length penalty of 10. Pairwise alignment parameters are Ktuple=1, gap penalty=3, windows=5, and diagonals=5.

Preferably, the trichodiene synthases of the present invention comprise the amino acid

sequence of SEQ ID NO. 2 or an allelic variant thereof; or a fragment thereof that has trichodiene synthase activity. In a more preferred embodiment, the trichodiene synthase of the present invention comprises the amino acid sequence of SEQ ID NO. 2. In another preferred embodiment, the trichodiene synthase of the present invention consists of the amino acid sequence of SEQ ID NO. 2 or an allelic variant thereof; or a fragment thereof that has trichodiene synthase activity. In another preferred embodiment, the polypeptide of the present invention consists of the amino acid sequence of SEQ ID NO. 2.

A fragment of SEQ ID NO. 2 is a polypeptide having one or more amino acids deleted from the amino and/or carboxyl terminus of this amino acid sequence. Preferably, a fragment contains at least 290 amino acid residues, more preferably at least 320 amino acid residues, and most preferably at least 350 amino acid residues.

An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

In a second embodiment, the present invention relates to isolated trichodiene synthases which are encoded by nucleic acid sequences which hybridize under very low stringency conditions, preferably low stringency conditions, more preferably medium stringency conditions, more preferably medium-high stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions with a nucleic acid probe which hybridizes under the same conditions with (i) nucleotides 2521 to 3686 of SEQ ID NO. 1, (ii) the cDNA sequence contained in nucleotides 2521 to 3686 of SEQ ID NO. 1, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii) (J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York). The subsequence of SEQ ID NO. 1 may be at least 100 nucleotides or preferably at least 200 nucleotides. Moreover, the subsequence may encode a polypeptide fragment which has trichodiene synthase activity. The polypeptides may also be allelic variants or fragments of the polypeptides that have trichodiene synthase activity.

The nucleic acid sequence of SEQ ID NO. 1 or a subsequence thereof, as well as the

amino acid sequence of SEQ ID NO. 2 or a fragment thereof, may be used to design a nucleic acid probe to identify and clone DNA encoding trichodiene synthases from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 35 nucleotides in length. Longer probes can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{35}\text{S}$ , biotin, avidin, fluorescein, or digoxigenin). Such probes are encompassed by the present invention.

Thus, a genomic DNA or cDNA library prepared from such other organisms may be screened for DNA which hybridizes with the probes described herein and which encodes a trichodiene synthase. Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA which is homologous with SEQ ID NO. 1 or a subsequence thereof, the carrier material is used in a Southern blot. For purposes of the present invention, hybridization indicates that the nucleic acid sequence hybridizes to a labeled nucleic acid probe corresponding to the nucleic acid sequence shown in SEQ ID NO. 1, its complementary strand, or a subsequence thereof, under very low to very high stringency conditions. Molecules to which the nucleic acid probe hybridizes under these conditions are detected using X-ray film.

In a preferred embodiment, the nucleic acid probe is a nucleic acid sequence which encodes the polypeptide of SEQ ID NO. 2, or a subsequence thereof. In another preferred embodiment, the nucleic acid probe is SEQ ID NO. 1. In another preferred embodiment, the nucleic acid probe is nucleotides 2521 to 3686 of SEQ ID NO. 1. In another preferred embodiment, the nucleic acid probe is the nucleic acid sequence contained in plasmid pTri5 which is contained in *Escherichia coli* NRRL B-30029, wherein the nucleic acid sequence encodes a trichodiene synthase. In another preferred embodiment, the nucleic acid probe is the mature polypeptide coding region contained in plasmid pTri5 which is contained in

*Escherichia coli* NRRL B-30029.

For long probes of at least 100 nucleotides in length, very low to very high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very  
5 low and low stringencies, 35% formamide for medium and medium-high stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures.

For long probes of at least 100 nucleotides in length, the carrier material is finally washed three times each for 15 minutes using 2 x SSC, 0.2% SDS preferably at least at 45°C  
10 (very low stringency), more preferably at least at 50°C (low stringency), more preferably at least at 55°C (medium stringency), more preferably at least at 60°C (medium-high stringency), even more preferably at least at 65°C (high stringency), and most preferably at least at 70°C (very high stringency).

For short probes which are about 15 nucleotides to about 70 nucleotides in length,  
15 stringency conditions are defined as prehybridization, hybridization, and washing post-hybridization at about 5°C to about 10°C below the calculated  $T_m$  using the calculation according to Bolton and McCarthy (1962, *Proceedings of the National Academy of Sciences USA* 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1  
20 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures.

For short probes which are about 15 nucleotides to about 70 nucleotides in length, the carrier material is washed once in 6X SSC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at about 5°C to about 10°C below the calculated  $T_m$ .

In a third embodiment, the present invention relates to variants of the trichodiene  
25 synthase having an amino acid sequence of SEQ ID NO. 2 comprising a substitution, deletion, and/or insertion of one or more amino acids.

The amino acid sequences of the variant polypeptides may differ from the amino acid sequence of SEQ ID NO. 2 or the mature polypeptide thereof by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues  
30 by different amino acid residues. Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or

activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

The polypeptides of the present invention have at least 20%, preferably at least 40%, more preferably at least 60%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 100% of the trichodiene synthase activity of the mature polypeptide of SEQ ID NO. 2.

In a preferred embodiment, a trichodiene synthase of the present invention is obtained from a *Fusarium venenatum* strain, and more preferably from *Fusarium venenatum* ATCC 20334 or a mutant strain thereof, *e.g.*, the polypeptide with the amino acid sequence of SEQ ID NO. 2.

As defined herein, an "isolated" trichodiene synthase is a polypeptide which is essentially free of other polypeptides, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably about 60% pure, even more preferably about 80% pure, most preferably about 90% pure, and even most preferably about 95% pure, as determined by SDS-PAGE.

The present invention also relates to isolated nucleic acid sequences which encode a trichodiene synthase of the present invention. In a preferred embodiment, the nucleic acid sequence is set forth in SEQ ID NO. 1. In another preferred embodiment, the nucleic acid

sequence is the sequence contained in plasmid pTri5 that is contained in *Escherichia coli* NRRL B-30029. In another preferred embodiment, the nucleic acid sequence is the mature polypeptide coding region of SEQ ID NO. 1. In another preferred embodiment, the nucleic acid sequence is the mature polypeptide coding region contained in plasmid pTri5 that is  
5 contained in *Escherichia coli* NRRL B-30029. The present invention also encompasses nucleic acid sequences which encode a polypeptide having the amino acid sequence of SEQ ID NO. 2, which differ from SEQ ID NO. 1 by virtue of the degeneracy of the genetic code. The present invention also relates to subsequences of SEQ ID NO. 1 which encode fragments of SEQ ID NO. 2 that have trichodiene synthase activity.

10 A subsequence of SEQ ID NO. 1 is a nucleic acid sequence encompassed by SEQ ID NO. 1 except that one or more nucleotides from the 5' and/or 3' end have been deleted. Preferably, a subsequence contains at least 870 nucleotides, more preferably at least 960 nucleotides, and most preferably at least 1050 nucleotides.

15 The present invention also relates to mutant nucleic acid sequences comprising at least one mutation in the mature polypeptide coding sequence of SEQ ID NO. 1, in which the mutant nucleic acid sequence encodes a polypeptide which consists of amino acids 1 to 380 of SEQ ID NO. 2.

20 The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are described herein. The nucleic acid sequence may be cloned from a strain of *Fusarium*, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence.

25 The term "isolated nucleic acid sequence" as used herein refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as determined by agarose electrophoresis. For example, an isolated nucleic acid sequence can be obtained by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced.

30 The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell



where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

The present invention also relates to nucleic acid sequences which have a degree of  
5 homology to nucleotides 2521 to 3686 of SEQ ID NO. 1 of at least about 97% homology, which encode a trichodiene synthase. For purposes of the present invention, the degree of homology between two nucleic acid sequences is determined by the Wilbur-Lipman method (Wilbur and Lipman, 1983, *Proceedings of the National Academy of Science USA* 80: 726-730) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI)  
10 with an identity table and the following multiple alignment parameters: Gap penalty of 10 and gap length penalty of 10. Pairwise alignment parameters are Ktuple=3, gap penalty=3, and windows=20.

Modification of a nucleic acid sequence encoding a trichodiene synthase of the present invention may be necessary for the synthesis of polypeptides substantially similar to  
15 the trichodiene synthase. The term "substantially similar" to the trichodiene synthase refers to non-naturally occurring forms of the polypeptide. These polypeptides may differ in some engineered way from the trichodiene synthase isolated from its native source, *e.g.*, variants that differ in specific activity, thermostability, pH optimum, or the like. The variant sequence may be constructed on the basis of the nucleic acid sequence presented as the polypeptide encoding part of SEQ ID NO. 1, *e.g.*, a subsequence thereof, and/or by  
20 introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleic acid sequence, but which correspond to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions which may give rise to a different amino acid  
25 sequence. For a general description of nucleotide substitution, see, *e.g.*, Ford *et al.*, 1991, *Protein Expression and Purification* 2: 95-107.

It will be apparent to those skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active polypeptide. Amino acid residues essential to the activity of the polypeptide encoded by the  
30 isolated nucleic acid sequence of the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed

mutagenesis or alanine-scanning mutagenesis (see, *e.g.*, Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique, mutations are introduced at every positively charged residue in the molecule, and the resultant mutant molecules are tested for trichodiene synthase activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can also be determined by analysis of the three-dimensional structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, *e.g.*, de Vos *et al.*, 1992, *Science* 255: 306-312; Smith *et al.*, 1992, *Journal of Molecular Biology* 224: 899-904; Wlodaver *et al.*, 1992, *FEBS Letters* 309: 59-64).

The present invention also relates to isolated nucleic acid sequences encoding a trichodiene synthase of the present invention, which hybridize under very low stringency conditions, preferably low stringency conditions, more preferably medium stringency conditions, more preferably medium-high stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions with a nucleic acid probe which hybridizes under the same conditions with the nucleic acid sequence of SEQ ID NO. 1 or its complementary strand; or allelic variants and subsequences thereof (Sambrook *et al.*, 1989, *supra*), as defined herein.

The present invention also relates to isolated nucleic acid sequences produced by (a) hybridizing a DNA under very low, low, medium, medium-high, high, or very high stringency conditions with (i) nucleotides 2521 to 3686 of SEQ ID NO. 1, (ii) the cDNA sequence contained in nucleotides 2521 to 3686 of SEQ ID NO. 1, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii); and (b) isolating the nucleic acid sequence. The subsequence is preferably a sequence of at least 100 nucleotides such as a sequence which encodes a polypeptide fragment which has trichodiene synthase activity.

In a preferred embodiment, the isolated nucleic acid sequence encoding a trichodiene synthase is obtained from *Fusarium venenatum*, and in a more preferred embodiment, the nucleic acid sequence is obtained from *Fusarium venenatum* ATCC 20334, *e.g.*, the nucleic acid sequence set forth in SEQ ID NO. 1. In another more preferred embodiment, the nucleic acid sequence is the sequence contained in plasmid pTri5 which is contained in *Escherichia coli* NRRL B-30029. The present invention also encompasses nucleic acid sequences which differ from SEQ ID NO. 1 by virtue of the degeneracy of the genetic code.

The nucleic acid sequences may be obtained from microorganisms which are taxonomic equivalents of *Fusarium venenatum* as defined by Yoder and Christianson, 1998, *supra*, and O'Donnell *et al.*, 1998, *supra*, regardless of the species name by which they are currently known.

5       The present invention further relates to methods for producing a mutant nucleic acid sequence, comprising introducing at least one mutation into the mature polypeptide coding sequence of SEQ ID NO. 1 or a subsequence thereof, wherein the mutant nucleic acid sequence encodes a polypeptide which consists of amino acids 1 to 380 of SEQ ID NO. 2 or a fragment thereof which has trichodiene synthase activity.

10       The introduction of a mutation into the nucleic acid sequence to exchange one nucleotide for another nucleotide may be accomplished by site-directed mutagenesis using any of the methods known in the art. Particularly useful is the procedure which utilizes a supercoiled, double stranded DNA vector with an insert of interest and two synthetic primers containing the desired mutation. The oligonucleotide primers, each complementary to  
15       opposite strands of the vector, extend during temperature cycling by means of *Pfu* DNA polymerase. On incorporation of the primers, a mutated plasmid containing staggered nicks is generated. Following temperature cycling, the product is treated with *DpnI* which is specific for methylated and hemimethylated DNA to digest the parental DNA template and to select for mutation-containing synthesized DNA. Other procedures known in the art may  
20       also be used.

25       The present invention also relates to nucleic acid constructs, recombinant expression vectors, and host cells containing the nucleic acid sequence of SEQ ID NO. 1, subsequences or homologues thereof, for expression of the sequences. The constructs and vectors may be constructed as described herein. The host cell may be any cell suitable for the expression of the nucleic acid sequence. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be a eukaryote, such as a mammalian, insect, plant, or fungal cell.

30       In a preferred embodiment, the host cell is a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as

defined by Hawksworth *et al.*, In, *Ainsworth and Bisby's Dictionary of The Fungi*, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth *et al.*, 1995, *supra*, page 171) and all mitosporic fungi (Hawksworth *et al.*, 1995, *supra*).

5 In a more preferred embodiment, the fungal host cell is a yeast cell. "Yeast" as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, 10 *Soc. App. Bacteriol. Symposium Series No. 9*, 1980).

In an even more preferred embodiment, the yeast host cell is a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell.

15 In a most preferred embodiment, the yeast host cell is a *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis* cell. In another most preferred embodiment, the yeast host cell is a *Kluyveromyces lactis* cell. In another most preferred embodiment, the yeast host cell is a *Yarrowia lipolytica* cell.

20 In another more preferred embodiment, the fungal host cell is a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth *et al.*, 1995, *supra*). The filamentous fungi are generally characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may 25 be fermentative.

In an even more preferred embodiment, the filamentous fungal host cell is a cell of a species of, but not limited to, *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma*.

30 In a most preferred embodiment, the filamentous fungal host cell is an *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger* or *Aspergillus oryzae* cell. In another most preferred embodiment, the filamentous fungal

host cell is a *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sporotrichioides*, *Fusarium sulphureum*,  
5 *Fusarium torulosum*, *Fusarium trichothecioides*, or *Fusarium venenatum* cell. In an even most preferred embodiment, the filamentous fungal parent cell is a *Fusarium venenatum* (Nirenberg sp. nov.) cell. In another most preferred embodiment, the filamentous fungal host cell is a *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium purpurogenum*, *Thielavia terrestris*,  
10 *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* cell.

Filamentous fungal cells may be transformed using the procedures described herein. Yeast may be transformed using the procedures described by Becker and Guarente, In  
Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology*,  
15 *Methods in Enzymology*, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *Journal of Bacteriology* 153: 163; and Hinnen *et al.*, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1920.

The present invention also relates to methods for producing a trichodiene synthase of the present invention comprising (a) cultivating a strain, which in its wild-type form is  
20 capable of producing the polypeptide, to produce a supernatant comprising the trichodiene synthase; and (b) recovering the trichodiene synthase. Preferably, the strain is of the genus *Fusarium*, and more preferably *Fusarium venenatum*.

The present invention also relates to methods for producing a trichodiene synthase of the present invention comprising (a) cultivating a host cell under conditions conducive for  
25 production of the trichodiene synthase; and (b) recovering the trichodiene synthase.

The present invention further relates to methods for producing a trichodiene synthase comprising (a) cultivating a homologously recombinant cell, having incorporated therein a new transcription unit comprising a regulatory sequence, an exon, and/or a splice donor site operably linked to a second exon of a nucleic acid sequence of the present invention which is  
30 endogenous to a cell, under conditions suitable for production of the trichodiene synthase encoded by the endogenous nucleic acid sequence; and (b) recovering the trichodiene

synthase. The methods are based on the use of gene activation technology, for example, as described in U.S. Patent No. 5,641,670.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the trichodiene synthase using methods known in the art as described herein. The trichodiene synthase may be detected using methods known in the art specific for the enzyme (see, *e.g.*, Hohn and Beremand, 1989, *Applied and Environmental Microbiology* 55: 1500-1503). The resulting trichodiene synthase may be recovered and purified by methods known in the art as described herein.

#### **Nitrate Reductase Selectable Marker-Free Mutant Cells**

The present invention also discloses the use of a nitrate reductase gene as a selectable marker for modifying a target gene or DNA element to reduce or eliminate the production of a gene product in a cell. The nitrate reductase gene may then be deleted from the cell to produce a cell that is free of the selectable marker.

The present invention therefore also relates to methods for obtaining a mutant cell, comprising: (a) introducing into a parent cell, having a nucleic acid sequence encoding a gene product, a nucleic acid construct comprising a nitrate reductase gene as a selectable marker and a modification of the nucleic acid sequence, wherein the construct incorporates into the genome of the parent cell replacing the nucleic acid sequence resulting in reduced production of the gene product compared to the parent cell when cultivated under the same conditions; and (b) selecting a mutant cell from step (a) for the presence of the nitrate reductase gene and reduced production of the gene product.

Nitrate reductase catalyzes the conversion of nitrate to nitrite which allows a cell to grow on nitrate as the sole nitrogen source. For cells that lack the possibility or only have a very limited capacity to use nitrate as the sole nitrogen source, the nitrate reductase gene in principle can be used as a selectable marker provided that nitrate is taken up by the cell. The nitrate reductase gene is preferably dominant in the cell of choice. The DNA coding for the nitrate reductase may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof, which produce a functional form of the enzyme.

The nitrate reductase gene may be obtained from any source using any of the recombinant methods described herein or known in the art. In a preferred embodiment, the

nitrate reductase gene is obtained from a fungal source, and more preferably from a yeast or filamentous fungal strain. In a more preferred embodiment, the nitrate reductase gene is obtained from *Neurospora crassa* (*nit3*, see, Fu and Marzluf, 1987, *Proceedings of the National Academy of Sciences USA* 84: 8243-8247). In another more preferred embodiment, the nitrate reductase gene is obtained from an *Aspergillus* strain (*niaD*), such as *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, and *Aspergillus parasiticus*. In another more preferred embodiment, the nitrate reductase gene is obtained from a *Fusarium* strain (*nia*), such as *Fusarium oxysporum*.

Modification of a target nucleic acid sequence may be accomplished using the methods for gene insertions, disruptions, replacements, or deletions described herein or known in the art. The genetic modification may be one or more nucleotide alterations, *e.g.*, insertions, deletions, and/or substitutions of the target nucleic acid sequence or a portion thereof such as, but not limited to, a coding region, signal sequence, promoter, terminator, intron, or regulatory DNA sequence. A nucleic acid construct comprising a modified version of the target nucleic acid sequence, or a portion thereof, is therefore constructed for the purpose of eliminating or reducing expression of the nucleic acid sequence. The construct is then transformed into the parent cell to produce a defective nucleic acid sequence where, by homologous recombination, the defective sequence replaces the target sequence or a portion thereof. The construct may be contained on a vector for introduction into the cell. The nitrate reductase gene is used as a selectable marker for identifying transformants containing the defective nucleic acid sequence.

The defective nucleic acid sequence may be a simple disruption of the target sequence with a nitrate reductase gene. Alternatively, the defective nucleic acid sequence may contain an insertion, substitution, and/or deletion of the target sequence, or a portion thereof, in addition to a disruption carried by the nitrate reductase gene. Furthermore, the defective nucleic acid sequence may contain an insertion, substitution, and/or deletion of the target sequence, or a portion thereof, where the nitrate reductase gene is not involved in the modification, but where the latter is contiguous with the defective sequence.

The nucleic acid construct may further comprise one or more repeat sequences at the 5' and 3' ends of the nitrate reductase gene to facilitate eventual deletion of the nitrate reductase gene. The repeats may be any nucleic acid sequence suitable for facilitating

intrachromosomal homologous recombination. The frequency of marker deletion is substantially increased by increasing the capacity of the gene to undergo intrachromosomal homologous recombination.

A useful property of the nitrate reductase is that it is able to convert chlorate to chlorite, which is toxic to cells. It is this property that forms the basis for another aspect of the present invention, *i.e.*, the production of transformants free of the nitrate reductase selectable marker. The chlorate converting property enables the counter-selection of transformed cells. Selected transformants containing the nitrate reductase gene are grown on a medium containing chlorate as the sole nitrogen source to identify those surviving transformants which have lost the nitrate reductase gene. Some of the surviving transformants may have mutations in the nitrate reductase gene itself. Therefore, deletion of the nitrate reductase gene should be confirmed, *e.g.*, by Southern hybridization.

Therefore, the methods for obtaining a mutant cell may further comprise (c) selecting a mutant cell from step (b) under culturing conditions in which the nitrate reductase gene is deleted. Alternatively, the methods for obtaining a mutant cell may further comprise (c) introducing into the mutant cell from step (b) a second nucleic acid construct comprising a second nucleic acid sequence comprising 5' and 3' regions of the modified nucleic acid sequence, but lacking the nitrate reductase gene, wherein the second construct incorporates into the genome of the parent cell replacing the modified nucleic acid sequence with the second nucleic acid sequence; and (d) selecting a mutant cell from step (c) under culturing conditions in which the nitrate reductase gene is deleted.

In both cases, the culturing conditions involve a counter-selection medium for nitrate reductase comprising chlorate.

A preferred construct for deleting a nitrate reductase gene as a selectable marker would contain the following elements in a 5' to 3' order: sequences 5' of the gene to be deleted, directly fused to sequences 3' of the gene to be deleted, followed downstream by a functional nitrate reductase gene, followed downstream by again sequences 3' of the gene to be deleted. In this case, both sequences 3' of the gene to be deleted are chosen such that they form repeats flanking the selectable marker gene. Transformation of this nucleic acid construct and subsequent replacement of the chromosome copy of the gene to be deleted by the nucleic acid construct with cross-over points in the sequences 5' and 3' of the gene to be



deleted results in deletion of the gene. Subsequent intrachromosomal recombination between the repeats flanking the selectable marker gene and counter-selection for these transformants finally results in a selection marker-free strain. The 5' and 3' repeats do not necessarily need to both be present in the construct, since single repeats may be used to delete the gene by a single cross-over integration. The construct(s) may be constructed in such a way that after deletion of the nitrate reductase gene, no extraneous nitrate reductase gene DNA remains in the chromosome of the transformed cell.

The construct(s) may be contained in a vector. The constructs and vectors may be prepared as described herein.

The methods of the present invention may be used to reduce or eliminate the production of one or more target gene products which are undesirable in the production of a protein (or compound) of interest, particularly where the target gene product(s) may be detrimental to the production, recovery, and/or application of the protein or compound. The methods may also be used to reduce or eliminate the biosynthesis of antibiotics and other bioactive compounds.

The cell may be a unicellular microorganism, *e.g.*, a prokaryote, or a non-unicellular microorganism, *e.g.*, a eukaryote such as a mammalian, insect, plant, or fungal cell.

In a preferred embodiment, the host cell is a fungal cell, such as a yeast or filamentous fungal cell. The yeast or fungal cell may be any of the cells described herein.

Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, *e.g.*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; or a *Streptomyces* cell, *e.g.*, *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas* sp.

The introduction of the construct into a bacterial cell may, for instance, be effected by protoplast transformation (see, *e.g.*, Chang and Cohen, 1979, *Molecular General Genetics* 168: 111-115), using competent cells (see, *e.g.*, Young and Spizizin, 1961, *Journal of Bacteriology* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, *Journal of Molecular Biology* 56: 209-221), electroporation (see, *e.g.*, Shigekawa and Dower, 1988, *Biotechniques*

6: 742-751), or conjugation (see, *e.g.*, Koehler and Thorne, 1987, *Journal of Bacteriology* 169: 5771-5278).

The present invention also relates to mutant cells produced by such methods. The mutant cells of the present invention may be used for the production of a polypeptide native or foreign to the mutant cell. The polypeptide may be any polypeptide such as those described herein. Expression of a polypeptide in a mutant cell of the present invention may be accomplished using the methods described herein.

The present invention also relates to methods for producing a polypeptide, comprising: (a) cultivating such a mutant cell comprising a nucleic acid sequence encoding a polypeptide under conditions conducive for the production of the polypeptide; and (b) isolating the polypeptide from the cultivation medium of the mutant cell. Methods for cultivation of a mutant and isolation of the polypeptide are described herein.

The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.

## Examples

### Materials

Chemicals used as buffers and substrates were commercial products of at least reagent grade.

### Strains

*Fusarium* strain A3/5, now reclassified as *Fusarium venenatum* (Yoder and Christianson, 1998, *Fungal Genetics and Biology* 23: 62-80; O'Donnell *et al.*, 1998, *Fungal Genetics and Biology* 23: 57-67), was obtained from Dr. Anthony Trinci, University of Manchester, Manchester, England, or from the American Type Culture Collection, Manassas, VA, as *Fusarium* strain ATCC 20334. *Fusarium venenatum* strain #93 (BBA 64537) was obtained from Biologische Bundesanstalt für Land- und Forstwirtschaft, Berlin, Germany. Morphological mutants of *Fusarium venenatum* A3/5 designated CC1-1, CC1-2, CC1-3, CC1-5, CC1-8, CC2-3, MC3-2, MC3-5, MC3-6, and MC3-9 (Wiebe *et al.*, 1992, *Mycological Research* 96: 555-562; Wiebe *et al.*, 1991, *Mycological Research* 95: 1284-

1288; Wiebe *et al.*, 1991, *Mycological Research* 96: 555-562) are highly branched, colonial variants. All of the following strains were derived from the *Fusarium venenatum* A3/5 morphological mutant CC1-3: *Fusarium venenatum* MLY3 (a derivative of CC1-3 which has identical complementation characteristics to CC1-3); *Fusarium venenatum* JRoy36-19B (CC1-3, xylanase<sup>+</sup>, bar<sup>+</sup>); *Fusarium venenatum* LyMC4 (CC1-3, tri5-deleted, amdS<sup>+</sup>, bar<sup>+</sup>, xylanase<sup>+</sup>); *Fusarium venenatum* LyMC4.B (CC1-3, tri5-deleted, amdS<sup>+</sup>, bar<sup>+</sup>, xylanase<sup>+</sup>, single-spore isolate of LyMC4); *Fusarium venenatum* LyMC4.C (CC1-3, tri5-deleted, amdS<sup>+</sup>, bar<sup>+</sup>, xylanase<sup>+</sup>, single-spore isolate of LyMC4); *Fusarium venenatum* LyMC19 (CC1-3, tri5-deleted, amdS<sup>+</sup>, bar<sup>+</sup>, xylanase<sup>+</sup>); *Fusarium venenatum* LyMC19.2 (CC1-3, tri5-deleted, amdS<sup>+</sup>, bar<sup>+</sup>, xylanase<sup>+</sup>, single-spore isolate of LyMC19); *Fusarium venenatum* LyMC19.5 (CC1-3, tri5-deleted, amdS<sup>+</sup>, bar<sup>+</sup>, xylanase<sup>+</sup>, single-spore isolate of LyMC19); *Fusarium venenatum* LyMC1 (MLY3, tri5-deleted); *Fusarium venenatum* LyMC1A (MLY3, tri5-deleted, amdS, single-spore isolate); *Fusarium venenatum* LyMC1B (MLY3, tri5-deleted, amdS, single-spore isolate); and *Fusarium venenatum* LyMC1C (MLY3, tri5-deleted, amdS, single-spore isolate).

## Media and Solutions

AMG trace metals solution was composed per liter of 14.3 g of ZnSO<sub>4</sub>·7H<sub>2</sub>O, 2.5 g of CuSO<sub>4</sub>·5H<sub>2</sub>O, 0.5 g of NiCl<sub>2</sub>, 13.8 g of FeSO<sub>4</sub>, 8.5 g of MnSO<sub>4</sub>, and 3.0 g of citric acid.

Biotin stock solution was composed of 5 mg of biotin in 100 ml of 50% ethanol.

COVE trace metals solution was composed per liter of 0.04 g of NaB<sub>4</sub>O<sub>7</sub>·10H<sub>2</sub>O, 0.4 g of CuSO<sub>4</sub>·5H<sub>2</sub>O, 1.2 g of FeSO<sub>4</sub>·7H<sub>2</sub>O, 0.7 g of MnSO<sub>4</sub>·H<sub>2</sub>O, 0.8 g of Na<sub>2</sub>MoO<sub>4</sub>·2H<sub>2</sub>O, and 10 g of ZnSO<sub>4</sub>·7H<sub>2</sub>O.

50X COVE salts solution was composed per liter of 26 g of KCl, 26 g of MgSO<sub>4</sub>·7H<sub>2</sub>O, 76 g of KH<sub>2</sub>PO<sub>4</sub>, and 50 ml of COVE trace metals.

COVE medium was composed per liter of 342.3 g of sucrose, 20 ml of 50X COVE salt solution, 1 mM acetamide, 1.5 mM CsCl<sub>2</sub>, and 25 g of Noble agar.

50X Vogels medium was composed per liter of 150 g of sodium citrate, 250 g of KH<sub>2</sub>PO<sub>4</sub>, 10 g of MgSO<sub>4</sub>·7H<sub>2</sub>O, 10 g of CaCl<sub>2</sub>·2H<sub>2</sub>O, 2.5 ml of biotin stock solution, and 5.0 ml of AMG trace metals solution.

COVE top agarose was composed per liter of 20 ml of 50X COVE salts, 0.8 M

sucrose, 15 mM cesium chloride, 10 mM acetamide, and 10 g of low melt agarose, pH adjusted to 6.0.

NY50 medium was composed per liter of 62.5 g of Nutriose 725, 2 g of  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 10 g of  $\text{KH}_2\text{PO}_4$ , 2 g of  $\text{K}_2\text{SO}_4$ , 2 g of citric acid, 10 g of yeast extract, 2 g of urea, 0.5 g of  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , and 0.5 ml of AMG trace metals, pH 6.0.

NYU35 medium was composed per liter of 35 g of maltodextrin, 1 g of  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 2 g of  $\text{KH}_2\text{PO}_4$ , 2 g of citric acid, 4 g of yeast extract, 1 g of urea, and 0.25 ml of AMG trace metals, pH 6.0.

RA sporulation medium was composed per liter of 50 g of succinic acid, 12.1 g of  $\text{NaNO}_3$ , 1 g of glucose, 20 ml of 50X Vogels, and 0.5 ml of a 10 mg/ml  $\text{NaMoO}_4$  stock solution, pH to 6.0.

YEG medium was composed per liter of 5 g of yeast extract and 20 g of glucose.

YEP medium was composed per liter of 10 g of yeast extract and 20 g of peptone.

YEPG medium was composed per liter of 10 g of yeast extract, 20 g of peptone, and 20 g of glucose.

Minimal medium was composed per liter of 6 g of  $\text{NaNO}_3$ , 0.52 g of KCl, 1.52 g of  $\text{KH}_2\text{PO}_4$ , 1 ml of COVE trace metals solution, 1 g of glucose, 500 mg of  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 342.3 g of sucrose, and 20 g of Noble agar at pH 6.5).

STC was composed of 0.8 M sorbitol, 25 mM Tris pH 8, 25 mM  $\text{CaCl}_2$ .

SPTC was composed of 40% PEG 4000, 0.8 M sorbitol, 25 mM Tris pH 8, 25 mM  $\text{CaCl}_2$ .

M400Da medium was composed per liter of 50 g of maltodextrin, 2 g of  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 2 g of  $\text{KH}_2\text{PO}_4$ , 4 g of citric acid, 8 g of yeast extract, 2 g of urea, and 1 ml of COVE trace metals solution.

Sporulation III medium was composed per liter of 20 mls of 50X Vogels, 4 g of glucose, 0.8 g of  $\text{NaNO}_3$ , and 1 ml of a 10 mg/ml  $\text{NaMoO}_4$  stock solution.

Vogels medium with BASTA™ (first stage seed inoculation) was composed of 20 ml of 50X Vogels, 5% glucose, 16.5 g of monobasic ammonium phosphate per liter, and 5 mg of BASTA™ per ml, pH 6.5.

Potassium chlorate medium for selection of *niaD* mutants was composed per liter of 20 mls of 50X COVE salts solution, 61.28 g of potassium chlorate, 0.3 g of urea, 25 g of

noble agar, and 2% glucose added after autoclaving.

Fluoroacetamide medium was composed per liter of 12 g of sodium acetate, 2 g of sodium chloride, 0.5 g of  $\text{MgSO}_4$ , 3 g of  $\text{KH}_2\text{PO}_4$ , 0.3 g of urea, 2 g of fluoroacetamide, 1 ml of Vogels salts, and 15 g of Noble agar, pH 6.1.

5 TAE buffer was composed per liter of 4.84 g of Tris Base, 1.14 ml of glacial acetic acid, and 2 ml of 0.5 M EDTA pH 8.0.

### Example 1: *Fusarium venenatum* ATCC 20334 genomic DNA extraction

10 *Fusarium venenatum* ATCC 20334 was grown in 25 ml of YEG medium for 24 hours at 28°C and 150 rpm. Mycelia were then collected by filtration through Miracloth (Calbiochem, La Jolla, CA) and washed once with 25 ml of 10 mM Tris-1 mM EDTA (TE) buffer. Excess buffer was drained from the mycelia which were subsequently frozen in liquid nitrogen. The frozen mycelia were ground to a fine powder in an electric coffee grinder, and the powder was added to 20 ml of TE buffer and 5 ml of 20% w/v sodium dodecylsulfate (SDS) in a disposable plastic centrifuge tube. The mixture was gently inverted several times to ensure mixing, and extracted twice with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v). Sodium acetate (3 M solution) was added to give a final concentration of 0.3 M and the nucleic acids were precipitated with 2.5 volumes of ice cold ethanol. The tube was centrifuged at 15,000 x g for 30 minutes and the pellet was allowed to air dry for 30 minutes before resuspension in 0.5 ml of TE buffer. DNase-free ribonuclease A was added to a concentration of 100 mg/ml and the mixture was incubated at 37°C for 30 min. Proteinase K (200 mg/ml) was then added and the mixture was incubated an additional hour at 37°C. Finally, the mixture was extracted twice with phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v) before precipitating the DNA with sodium acetate and ethanol according to standard procedures. The DNA pellet was dried under vacuum, resuspended in TE buffer, and stored at 4°C.

### Example 2: Preparation of a *Fusarium venenatum* ATCC 20334 trichodiene synthase probe

30 Based on the conserved amino acid sequences of the trichodiene synthases from *Fusarium sporotrichioides*, *Fusarium poae*, and *Gibberella pulicaris*, the oligonucleotide

primers shown below were synthesized with an Applied Biosystems Model 394 DNA/RNA Synthesizer, according to the manufacturer's instructions, to PCR amplify a trichodiene synthase gene fragment from *Fusarium venenatum* ATCC 20334 genomic DNA.

Primer 1: 5'-GGCTGCTCATCACTTTGCTC-3' (SEQ ID NO. 3)

5 Primer 2: 5'-TGCATGAAGCACTCAATCGT-3' (SEQ ID NO. 4)

Amplification reactions (50 µl) were prepared using approximately 0.8 µg of *Fusarium venenatum* genomic DNA, prepared as described in Example 1, as the template. Each reaction contained the following components: 0.8 µg of genomic DNA, 40 pmol of primer 1, 40 pmol of primer 2, 200 µM each of dATP, dCTP, dGTP, and dTTP, 1 x *Taq* DNA polymerase buffer (Perkin-Elmer Corp., Branchburg, NJ), and 2.5 Units of *Taq* DNA polymerase (Perkin-Elmer Corp., Branchburg, NJ). The reactions were incubated in a Perkin-Elmer Model 480 Thermal Cycler programmed for 30 cycles each at 95°C for 3 minutes, 58°C for 2 minutes, and 72°C for 2 minutes. The reaction products were isolated on a 1.5% agarose gel (Eastman Kodak, Rochester, NY) where a 812 bp product band was excised from the gel and purified using Qiaex II (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. The purified PCR product was subsequently cloned into a pCRII vector (Invitrogen, San Diego, CA) and the DNA sequence was determined using *lac* forward and reverse primers (New England BioLabs, Beverly, MA).

DNA sequence analysis showed that the amplified gene fragment encoded a portion of the corresponding *Fusarium venenatum* trichodiene synthase gene based on sequence comparison with the *Fusarium sporotrichioides*, *Fusarium poae*, and *Gibberella pulicaris* trichodiene synthase gene sequences. The trichodiene synthase gene fragment (812 kb) was PCR-labeled with digoxigenin using a DIG Kit (Boehringer Mannheim Corp., Indianapolis, IN) according to the manufacturer's instructions to probe a *Fusarium venenatum* genomic DNA library.

### Example 3: DNA libraries and identification of *tri5* clones

Genomic DNA libraries were constructed using the bacteriophage cloning vector λZipLox (Life Technologies, Gaithersburg, MD) with *E. coli* Y1090ZL cells (Life Technologies, Gaithersburg, MD) as a host for plating and purification of recombinant bacteriophage and *E. coli* DH10Bzip (Life Technologies, Gaithersburg, MD) for excision of

individual pZL1-*tri5* clones. Total cellular DNA was partially digested with *Tsp509I* and size-fractionated on 1% agarose gels. DNA fragments migrating in the size range 3-8 kb were excised and eluted from the gel using Qiaex (Qiagen Inc., Chatsworth CA). The eluted DNA fragments were ligated with *EcoRI*-cleaved and dephosphorylated  $\lambda$ ZipLox vector arms (Life Technologies, Gaithersburg, MD), and the ligation mixtures were packaged using commercial packaging extracts (Stratagene, La Jolla, CA). The packaged DNA libraries were plated and amplified in *Escherichia coli* Y1090ZL cells (Life Technologies, Gaithersburg, MD). The amplified genomic library contained  $1.4 \times 10^7$  pfu/ml. Approximately 30,000 plaques from the library were screened by plaque-hybridization with the non-radioactive digoxigenin described in Example 2 using standard procedures (see, Sambrook *et al.*, 1989, *supra*).

Three positive clones which hybridized strongly to the probe were picked and two were purified twice in *E. coli* Y1090ZL cells. The two *tri5* clones, pSMO129 and pSMO130, were subsequently excised from the  $\lambda$ ZipLox vector as pZL1-*tri5* clones (D'Alessio *et al.*, 1992, *Focus*® 14: 76).

#### **Example 4: DNA sequence analysis of *Fusarium venenatum tri5* gene**

DNA sequencing of the *tri5* clones, pSMO129 and pSMO130, was performed with an Applied Biosystems Model 373A Automated DNA Sequencer (Applied Biosystems, Inc., Foster City, CA). In addition to the *lac*-forward and *lac*-reverse primers, specific oligonucleotide sequencing primers were synthesized on an Applied Biosystems Model 394 DNA/RNA Synthesizer according to the manufacturer's instructions.

DNA sequencing of the clones designated pSMO129 and pSMO130 showed that neither clone contained the complete sequence of the gene, but contained overlapping sequences from which was obtained the DNA sequence of the entire gene. The combined DNA sequence of the two sequences revealed an open reading frame as shown in Figure 2 (SEQ ID NO. 1).

A single clone containing the entire gene fragment was constructed from the two overlapping clones pSO130 and pSO129. pSO129 and pSO130 were digested with the restriction enzyme *SacI* and then run on a 1% agarose gel. The appropriate fragments were then gel isolated using a QIAquick Gel Extraction Kit (Qiagen, Chatsworth, CA) and ligated

overnight at 14°C using standard methods to produce pTri5. The ligation was then transformed into *E. coli* strain DH5α by standard methods. Plasmid DNA from a putative full length clone was isolated using a Qiagen MaxiPrep kit (Qiagen, Chatsworth, CA) and DNA sequenced using an Applied Biosystems Model 373A Automated DNA Sequencer which confirmed the sequence was identical to SEQ ID NO. 1. The clone was designated *E. coli* DH5α pTri5.

The positions of introns and exons within the *Fusarium venenatum* ATCC 20334 trichodiene synthase gene were assigned based on alignments of the deduced amino acid sequence (SEQ ID NO. 2) to the corresponding *Fusarium poae* trichodiene synthase gene product (SEQ ID NO. 5). On the basis of this comparison, the *Fusarium venenatum* ATCC 20334 trichodiene synthase gene was composed of 2 exons (1-469 bp and 529-1203 bp) which were interrupted by 1 small intron (470-528 bp). The size and composition of the intron were consistent with those of other fungal genes (Gurr *et al.*, 1987, *In* Kinghorn, J.R. (ed.), *Gene Structure in Eukaryotic Microbes*, pp. 93-139, IRL Press, Oxford) in that it contained consensus splice donor and acceptor sequences as well as the consensus lariat sequence (PuCTPuAC) near the 3' end of each intervening sequence.

The trichodiene synthase is an acidic protein (calculated isoelectric point = 5.37) composed of 380 amino acids (MW = 44562).

A comparative alignment of trichodiene synthase deduced amino acid sequences was undertaken using the Clustal method (Higgins, 1989, *CABIOS* 5: 151-153) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10 and gap length penalty of 10. Pairwise alignment parameters were Ktuple=1, gap penalty=3, windows=5, and diagonals=5.

The comparative alignment showed that the deduced amino acid sequence of the *Fusarium venenatum* ATCC 20334 trichodiene synthase shared approximately 96.3% identity with the *Fusarium poae* trichodiene synthase (Fekete *et al.*, 1997, *Mycopathologia* 138: 91-97) (SEQ ID NO. 5).

### **Example 5: Construction of pJRoy36**

pJRoy36 was constructed to obtain expression of *Thermomyces lanuginosus*



(formerly designated *Humicola lanuginosa*) xylanase in *Fusarium venenatum*.

pDM181 was constructed using the technique of splice overlap extension to fuse the 1.2 kb *Fusarium oxysporum* trypsin promoter to the 1.1 kb *Fusarium oxysporum* trypsin terminator (SP387). A polylinker containing *Swa*I, *Kpn*I and *Pac*I restriction sites was inserted between the promoter and terminator as part of the overlapping PCR strategy. At the 5' end of the promoter a *Xho*I site was added and the native *Eco*RI site was preserved. At the 3' end of the terminator *Eco*RI, *Hind*III and *Nsi*I sites were incorporated by the PCR reaction.

A PCR fragment containing -1208 to -1 of the *Fusarium oxysporum* trypsin promoter plus a 25 base pair polylinker was generated from plasmid pJRoy20 (Royer *et al.*, 1995, *Biotechnology* 13: 1479-1483) using the following primers:

Primer 1 (sense):

*Xho*I      *Eco*RI

5'-GAGCTCGAGGAATTCTTACAAACCTTCAAC-3' (SEQ ID NO. 6)

Primer 2 (antisense):

*Pac*I      *Kpn*I      *Swa*I

5'-TTAATTAAGGTACCTGAATTAAATGGTGAAGAGATAGATATCCAAG-3' (SEQ ID NO. 7)

The 100 µl PCR reaction contained 1X *Pwo* buffer (Boehringer Mannheim, Indianapolis, IN), 200 µM each of dATP, dCTP, dGTP, and dTTP, 10 ng of pJRoy20, and 5 units of *Pwo* DNA polymerase (Boehringer Mannheim, Indianapolis, IN). PCR conditions used were 95°C for 3 minutes followed by 25 cycles each at 95°C for 30 seconds, 50°C for 1 minute, and 72°C for 1 minute. The final extension cycle was at 72°C for 5 minutes.

Using the same PCR conditions, a second PCR fragment containing bp -5 to -1 of the *Fusarium oxysporum* trypsin promoter, a 25 base pair polylinker, and 1060 base pairs of the 3' untranslated region of the *Fusarium oxysporum* trypsin gene (terminator region) was generated from plasmid pJRoy20 using the following primers:

Primer 3 (sense):

*Swa*I      *Kpn*I      *Pac*I

5'-TCACCATTTAAATTCAGGTACCTTAATTAATTCCTTGTTGGAAGCGTCGA-3' (SEQ ID NO. 8)

Primer 4 (antisense):

*Nsi*I    *Hind*III    *Eco*RI

5'-TGGTATGCATAAGCTTGAATTCAGGTAAACAAGATATAATTT-3' (SEQ ID NO. 9)

The final 2.3 kb overlapping PCR fragment which contained -1208 to -1 of the *Fusarium oxysporum* trypsin promoter, the 25 base pair polylinker, and 1060 base pairs of the *Fusarium oxysporum* trypsin terminator was obtained using 0.2 µl of the first PCR (promoter) reaction and 3 µl of the second (terminator) reaction as templates and primers 1 and 4. The PCR conditions used were 95°C for 3 minutes followed by 30 cycles each at 95°C for 30 seconds, 62°C for 1 minute, and 72°C for 3 minutes. The final extension cycle was at 72°C for 5 minutes. *Pwo* DNA polymerase was also used for this reaction.

The resulting 2.3 kb fragment containing the trypsin promoter, the polylinker, and the trypsin terminator was digested with *Eco*RI and ligated into the *Eco*RI digested vector pMT1612 containing the *bar* gene (WO 97/26330) to create pDM181 (Figure 3).

The xylanase fragment was also generated by PCR. Plasmid pHD414 (WO 93/11249) which contains the cDNA of the *Thermomyces lanuginosus* xylanase gene was used as the template. PCR primers 5 and 6 were used to introduce the sequence CCACC at the 5' end and a *Pac*I site at the 3' end of the xylanase coding sequence.

Primer 5 (sense)

5'-CCACCATGGTCGGCTTTACCCCCGTT-3' (SEQ ID NO. 10)

Primer 6 (anti-sense)

5'-GGTTAATTAATTAGCCACGTCAGCAACGGT-3' (SEQ ID NO. 11)

*Pac*I

The PCR conditions used were 95°C for three minutes followed by 25 cycles each at 95°C for 1 minute, 62°C for one minute, and 72°C for three minutes. Reaction volumes were as previously described. DMSO was included at 5% v/v.

The resulting 0.7 kb xylanase fragment was digested with *Pac*I and ligated to *Swa*I/*Pac*I digested pDM181 yielding plasmid pJRoy36 (Figure 4).

#### Example 6: Construction of *Fusarium venenatum* JRoy36-19B and expression of xylanase gene

Spores of *Fusarium venenatum* CC1-3 were generated by inoculating a flask

containing 500 ml of RA sporulation medium with 10 plugs from a 1X Vogels medium plate (2.5% Noble agar) supplemented with 2.5% glucose and 2.5 mM sodium nitrate and incubating at 28°C, 150 rpm for 2 to 3 days. Spores were harvested through Miracloth (Calbiochem, San Diego, CA) and centrifuged 20 minutes at 7000 rpm in a Sorvall RC-5B centrifuge (E. I. DuPont De Nemours and Co., Wilmington, DE). Pelleted spores were washed twice with sterile distilled water, resuspended in a small volume of water, and then counted using a hemocytometer.

Protoplasts were prepared by inoculating 100 ml of YEPG medium with  $4 \times 10^7$  spores of *Fusarium venenatum* CC1-3 and incubating for 16 hours at 24°C and 150 rpm. The culture was centrifuged for 7 minutes at 3500 rpm in a Sorvall RT 6000D (E. I. DuPont De Nemours and Co., Wilmington, DE). Pellets were washed twice with 30 ml of 1 M  $\text{MgSO}_4$  and resuspended in 15 ml of 5 mg/ml of NOVOZYME 234™ (batch PPM 4356, Novo Nordisk A/S, Bagsværd, Denmark) in 1 M  $\text{MgSO}_4$ . Cultures were incubated at 24°C and 150 rpm until protoplasts formed. A volume of 35 ml of 2 M sorbitol was added to the protoplast digest and the mixture was centrifuged at 2500 rpm for 10 minutes. The pellet was resuspended, washed twice with STC, and centrifuged at 2000 rpm for 10 minutes to pellet the protoplasts. Protoplasts were counted with a hemocytometer and resuspended in an 8:2:0.1 solution of STC:SPTC:DMSO to a final concentration of  $1.25 \times 10^7$  protoplasts/ml. The protoplasts were stored at -80°C, after controlled-rate freezing in a Nalgene Cryo 1°C Freezing Container (VWR Scientific, Inc., San Francisco, CA).

Frozen protoplasts of *Fusarium venenatum* CC1-3 were thawed on ice. Five  $\mu\text{g}$  of pJRoy36 described in Example 5 and 5  $\mu\text{l}$  of heparin (5 mg per ml of STC) were added to a 50 ml sterile polypropylene tube. One hundred  $\mu\text{l}$  of protoplasts were added, mixed gently, and incubated on ice for 30 minutes. One ml of SPTC was added and incubated 20 minutes at room temperature. After the addition of 25 ml of 40°C COVE top agarose supplemented with 10-25 mM sodium nitrate in place of 10 mM acetamide and 10 mM cesium chloride, the mixture was poured onto an empty 150 mm diameter plate and incubated overnight at room temperature. Then an additional 25 ml of 40°C COVE top agarose supplemented with 10-25 mM sodium nitrate in place of 10 mM acetamide and 10 mM cesium chloride and containing 10 mg of BASTA™ per ml was poured on top of the plate and incubated at room temperature for up to 14 days. The active ingredient in the herbicide BASTA™ is phosphinothricin.

BASTA™ was obtained from AgrEvo (Hoechst Schering, Rodovre, Denmark) and was extracted twice with phenol:chloroform:isoamyl alcohol (25:24:1), and once with chloroform:isoamyl alcohol (24:1) before use.

Plugs from the plates (COVE underlay with COVE-BASTA™ overlay as above) of the transformants were inoculated into shake flasks containing 30 ml of M400Da medium and incubated at 30°C, 150 rpm for 7 days. Flasks were sampled at 7 days and supernatants were assayed for xylanase activity.

Xylanase activity was determined as follows. The reactions were initiated by the addition of 90 µl of a substrate solution containing 0.5% AZO-WAX™ (Megazyme, Dublin, Ireland) in 0.1 M sodium phosphate pH 6.0 buffer to 10 µl of each enzyme sample solution, diluted as appropriate in 0.1 M sodium phosphate pH 6.0 buffer. The reactions were incubated at 50°C for 30 minutes and then quenched by adding 500 µl of ethanol that had been acidified with 0.55 µl of concentrated HCl. The resulting mixtures were allowed to stand at room temperature for at least 10 minutes, but no longer than 60 minutes. The samples were then centrifuged at 12,000 rpm for 2 minutes. A 200 µl aliquot of each supernatant was transferred to a microtiter plate and the absorbance was measured at 600 nm.

Activity was calculated by reference to a BIOFEED WHEAT™ standard obtained from Novo Nordisk A/S, Bagsværd, Denmark, using a standard curve generated with a 1.0 FXU per ml standard added in volumes of 10, 20, 40, 60, 80, 90, and 100 µl. For this purpose, a 10 FXU/ml standard was prepared initially and then diluted 1:10 with 0.1 M sodium phosphate pH 6.0 buffer for use as the working standard. A blank (substitute buffer for enzyme) was included for generation of the standard curve using linear regression.

A single transformed colony designated *Fusarium venenatum* pJRoy36-19.B was selected based on the xylanase assay results.

#### **Example 7: Construction of pJRoy40**

A deletion plasmid, pJRoy40, was created which contained approximately 1.5 kb of 5' flanking DNA and 1.5 kb of 3' flanking DNA of the *Fusarium venenatum tri5* gene joined by a *Bgl*II site. pSO129 and pSO130, described in Example 3, were digested with both *Not*I and *Bgl*III. The 5.5 kb fragment of pSO130, containing the vector pZL1 plus bp 0-1694 of *tri5* DNA, was ligated to the 1.5 kb fragment of pSO129, corresponding to bp 5413-6946 of

*tri5* DNA plus a small amount of the polylinker. This resulted in pJRoy40 (Figure 5) which contained 1.5 kb of *tri5* 5' DNA and 1.7 kb of *tri5* 3' DNA. The coding region for *tri5* was bp 2475-3678. Approximately 3.7 kb of DNA, encompassing the entire *tri5* coding region, had been removed.

5

#### Example 8: Construction of *tri5::amdS* deletion fragment

pJRoy40 was digested with *Bgl*II, which forms the junction between the 5' and 3' regions. The ends were filled in with the Klenow fragment according to Sambrook *et al.*, 1989, *supra*, and the linearized vector was purified by 1% agarose gel electrophoresis using  
10 TAE buffer and agarase treatment. The vector was next treated with calf intestinal alkaline phosphatase according to Sambrook *et al.*, 1989, *supra*. The *amdS* gene was isolated from pBANe20 (Figure 6) and inserted as a blunt fragment into the *Bgl*II site of pJRoy40, resulting in pLC30 (Figure 7).

The 5670 bp *Eco*RI fragment containing the *tri5* deletion cassette was isolated from  
15 pLC30 by gel purification using the QIAquick Gel Extraction Kit. The gel-purified deletion fragment was used to transform protoplasts of *Fusarium venenatum* JRoy36-19B.

#### Example 9: Construction of *tri5* hybridization probes

DIG-labeled probes were obtained by PCR amplification. For a 5' probe ("*tri5*  
20 flanking probe"), the amplification reaction contained the following components: 50 ng of pSO130, 100 µM each of DIG-labeled dATP, dCTP, dGTP, and dTTP, 50 pmoles each of primers *tri5* 5' probe 5'-AACTGGAAAGACCTGTGGGC-3' (bp 928-947) (SEQ ID NO. 12) and pSO130 5'-1442 probe 5'-GGGAAATAGTGTCACGCGTA-3' (bp 1379-1399) (SEQ ID NO. 13), 2 units of *Taq* DNA polymerase, and 1X *Taq* DNA polymerase buffer. The  
25 reaction was incubated in a Perkin-Elmer Thermal Cycler programmed for 30 cycles each at 95°C for 1 minute, 55°C for 1 minute, and 72°C for 90 seconds. The resulting fragment ("*tri5* flanking probe") was gel isolated using GenElute Spin Columns (Supelco, Bellefonte, CA) and quantified with DIG Quantification Test Strips (Boehringer Mannheim, Indianapolis, IN) according to the manufacturers' instructions.

30 The conditions for generation of the open reading frame probe ("*tri5* open reading frame probe") were identical, except that the following primers were used: primer 970590

5'-GGACAACAGCCGAACTCAAAC-3' (bp 2036-2057) (SEQ ID NO. 14) and primer 970478 5'-GTGCTGCGGATAAGGTTC-3' (bp 2919-2937) (SEQ ID NO. 15). The resulting fragment ("*tri5* open reading frame probe") was isolated and quantified as above.

The fluorescein-labeled probes were made by amplifying the same PCR products as described above. The products were gel purified using the QIAquick Gel Extraction Kit according to the manufacturer's instructions. The purified fragments were fluorescein-labeled using the "Random Prime Labeling Module" for the Fluorimager (Amersham, Sunnyvale, CA) according to the manufacturer's instructions.

#### **Example 10: Replacement of the *Fusarium venenatum* JRoy36-19B native *tri5* gene with a deletion fragment**

Spores of *Fusarium venenatum* JRoy36-19B were generated by inoculating a flask containing 500 ml of RA sporulation medium with 10 plugs from an agar plate containing 5 mg of BASTA™ per ml and incubated at 28°C, 150 rpm for 2 to 3 days. Spores were harvested through Miracloth and centrifuged 20 minutes at 7000 rpm in a Sorvall RC-5B centrifuge. Pelleted spores were washed twice with sterile distilled water, resuspended in a small volume of water, and then counted using a hemocytometer.

Protoplasts were prepared by inoculating 100 ml of YEG medium with  $4 \times 10^7$  spores of *Fusarium venenatum* JRoy36-19B and incubating for 16 hours at 24°C and 150 rpm. The culture was centrifuged for 7 minutes at 3500 rpm in a Sorvall RT 6000D. Pellets were washed twice with 30 ml of 1 M MgSO<sub>4</sub> and resuspended in 20 ml of 5 mg/ml of NOVOZYME 234™ in 1 M MgSO<sub>4</sub>. Cultures were incubated at 24°C and 150 rpm until protoplasts formed. A volume of 35 ml of 2 M sorbitol was added to the protoplast digest and the mixture was centrifuged at 2500 rpm for 10 minutes. The pellet was resuspended, washed twice with STC, and centrifuged at 2000 rpm for 10 minutes to pellet the protoplasts.

Protoplasts were counted with a hemocytometer and resuspended in an 8:2:0.1 solution of STC:SPTC:DMSO to a final concentration of  $1.25 \times 10^7$  protoplasts/ml. The protoplasts were stored at -80°C, after controlled-rate freezing in a Nalgene Cryo 1°C Freezing Container.

Frozen protoplasts of *Fusarium venenatum* JRoy36-19B were thawed on ice. Five µg of the gel purified *tri5* deletion fragment described in Example 8 were added to a 50 ml

sterile polypropylene tube. One hundred  $\mu$ l of protoplasts were added, mixed gently, and incubated on ice for 30 minutes. One ml of SPTC was added and incubated 20 minutes at room temperature. After the addition of 25 ml of 40°C COVE top agarose, the mixture was poured onto a 150 mm diameter COVE agar plate. Transformation plates were incubated at room temperature for up to 14 days.

Transformants were selected by growth on COVE plates, which required the ability to use acetamide as a nitrogen source and thus indicated the integration of the *amdS* gene. More than 145 transformants (from a total of 20 transformations) grew on the COVE plates, and 20 of these transformants were tested for 4,15-diacetoxyscirpenol (DAS) production.

DAS production was induced according to the following protocol. Spore stocks were generated by inoculation of 500 ml of RA sporulation medium in 2 liter Fernbach shake flasks with twelve agar plugs (~ 5 X 5 mm) cut from Minimal medium plates. The Fernbach shake flasks were incubated at 28°C and 150 rpm for 40 hours. The cultures were then harvested through sterile Miracloth into sterile 50 ml Falcon tubes and their concentrations adjusted to  $2 \times 10^7$  spores/ml, after counting using a haemocytometer slide. Spore stocks were either used immediately or stored at 5°C for one or two weeks. Two ml of the  $2 \times 10^7$  spores/ml spore stock (freshly generated or one or two weeks old) were inoculated into 50 ml of MYRO medium in 250 ml glass baffled shake flasks in triplicate. The shake flasks were incubated at 28°C and 220 rpm, in the light, for 7 days. After 7 days, the contents of each shake flask were filtered through sterile Miracloth, their pH measured, and stored at -20°C prior to DAS analysis.

DAS was extracted and quantified by the method of McCormick *et. al.*, 1990, *supra*, with slight modifications. Cell-free *Fusarium venenatum* broth samples (1.0 ml) were extracted twice with two volumes of ethyl acetate (2.0 ml). The combined organic extracts were evaporated to dryness under a stream of nitrogen gas and derivatized with 50 microliters of TriSil/TBT (Pierce Chemical Co., Rockford, IL) at 80°C for 60 minutes. The final sample volume was then adjusted to 0.5 ml with hexane.

One microliter of each sample was analyzed on a Hewlett-Packard 6890 gas chromatograph equipped with a 30 meter DB-1 column (J&W Scientific, Folsom, CA; 250 micrometer diameter, 0.25 micrometer film thickness) and FID detector. The injection procedure used the splitless mode with a 260°C inlet and a nitrogen carrier gas flow of 1.2

ml/minute. The oven program was 180°C initial temperature; heating at 30°C per minute to 210°C; heating at 5°C per minute to 260°C; and held at final temperature for 2 minutes. Diacetoxyscirpenol identification and quantification was based on standard material obtained from Sigma Chemical Co. (St. Louis, MO). Under these conditions, the limit of detection  
5 was 2 ppm for DAS.

Twelve of the 20 transformants tested did not produce any detectable DAS. Plugs from the COVE plates of these twelve transformants were inoculated into triplicate shake flasks according to the following protocol for xylanase assays. A seed build-up method was used to inoculate shake flask cultures. Thirty ml of Vogels medium supplemented with 5 mg  
10 of BASTA™ per ml were inoculated with an agar plug from a fresh plate of each strain tested and then incubated 3 days at 28°C at 200 rpm. One hundred and fifty µl of each culture were then used to inoculate 30 ml of NY50 medium with 5 mg/ml BASTA™. After 2 days of growth at 28°C and 200 rpm, 1.5 ml of each culture was transferred to 30 ml of NYU35 medium without BASTA™ and incubated under the same condition for 4-7 days. Flasks  
15 were sampled at 4-7 days and supernatants were assayed for xylanase activity. The three highest xylanase producers were then submitted to Southern analysis to confirm the *tri5* gene had been deleted.

Southern hybridizations were performed using the Vistra Kit (Amersham, Arlington, IL) and Rapid Hyb Kit (Amersham, Arlington, IL) according to the manufacturer's  
20 instructions. Fungal genomic DNA from the *Fusarium venenatum* JRoy36-19B putative deletants was prepared using the DNeasy Plant Mini Kit (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. One µg of genomic DNA was digested with *Sph*I and *Dra*I and electrophoresed on an agarose gel. After denaturation and neutralization, the genomic DNA was transferred to a Hybond-N<sup>+</sup> membrane (Amersham, Arlington, IL) using a  
25 Turboblotter (Schleicher & Schuell, Keene, NH). After prehybridization with Rapid Hyb at 60°C, membranes were hybridized with denatured probe (see below) overnight at 60°C. Membranes were developed following the manufacturer's instructions and scanned using a STORM 860 (Molecular Dynamics, Sunnyvale, CA) according to the manufacturer's instructions.

30 The "*tri5* flanking probe" (fluorecein-labeled, Example 9) hybridized in the 5' flanking region 765 nucleotides upstream of the *amdS* insertion. The "*tri5* open reading



frame probe" (fluorecein-labeled, Example 9) hybridized approximately 450 nucleotides downstream of the *tri5* ATG.

The results of the Southern hybridization analysis confirmed the deletion of the *tri5* gene in the three DAS-negative, high xylanase producing transformants *Fusarium venenatum* LyMC4, LyMC19, and LyMC21. The probe that hybridized to the 5' flanking region of *tri5* hybridized to a band corresponding to the size of the deletion construct and did not hybridize to bands corresponding to the native *tri5* gene indicated replacement of the region with the deletion construct. Additionally, the probe that bound to the open reading frame of *tri5* failed to hybridize in these strains, indicating the loss of the gene.

#### **Example 11: Xylanase production of *Fusarium venenatum* LyMC4, LyMC19, and LyMC21 grown with phosphinothricin resistance selection**

*Fusarium venenatum* LyMC4, LyMC19, and LyMC21 were subcultured from the original COVE transformation plates described in Example 10 onto plates containing 5 mg/ml of BASTA™ and incubated at 28°C for 7-10 days. Plugs from the BASTA™ plates of these isolates were used to inoculate triplicate shake flasks according to the protocol for xylanase assays outlined in Example 10. Flasks were sampled at days 4, 5, 6, and 7 and supernatants were assayed.

Xylanase activity was determined as described in Example 6 from samples taken on days 4, 5, 6, and 7 from the flasks. *Fusarium venenatum* LyMC4 and LyMC19 produced xylanase amounts equivalent to or higher than the parental strain *Fusarium venenatum* JRoy36-19B, and these strains were further analyzed.

#### **Example 12: Analysis of high xylanase-producing deletants *Fusarium venenatum* LyMC4 and LyMC19**

Single-spore isolates from the two high-producing *Fusarium venenatum* strains LyMC4 and LyMC19 were selected on BASTA™ medium as described in Example 6. Five single-spore isolates of each were maintained on phosphinothricin resistance selection.

Southern hybridization analysis was conducted on the genomic DNA obtained from the five single-spore isolates as described in Example 10.

Southern hybridization confirmed the *tri5* gene deletion in all the single-spore

isolates. When probed with the fluorescein-labeled probe that binds upstream of the deleted region of the *tri5* gene (“Tri5 flanking probe”), all strains had a band corresponding to the size of the deletion cassette, compared to the size of the native *tri5* region band of *Fusarium venenatum* JRoy36-19B. The parental strain *Fusarium venenatum* LyMC19 had a faint band  
 5 corresponding to the wild type *tri5* gene, which probably indicated that a small population of nuclei were not deleted. However, all single spore isolates obtained from that strain harbored the deletion. When these same strains were hybridized with the fluorescein-labeled probe that binds to the *tri5* open reading frame (“Tri5 open reading frame probe”), only *Fusarium venenatum* JRoy36-19B and *Fusarium venenatum* LyMC19 had bands corresponding to the  
 10 open reading frame of *tri5*. The band from *Fusarium venenatum* LyMC19 was very faint and none of the single-spore isolates from that strain had bands, indicating that even before single-spore purification the majority of nuclei were probably deleted of the *tri5* gene. The data from both hybridizations indicated that the *tri5* open reading frame had been replaced with the *amdS* deletion cassette in all single-spore isolates.

15 **Example 13: DAS assays of *Fusarium venenatum* LyMC4- and LyMC19-derived strains**

The single-spore isolates *Fusarium venenatum* LyMC4.B, LyMC4.C, LyMC19.2, and LyMC19.5, the parental strains *Fusarium venenatum* LyMC4 and LyMC19, and control  
 20 strains were analyzed for DAS production using the protocols described in Example 10.

All strains were grown in triplicate shake flasks and assayed in the same run. The results of each assay are listed below in Table 1 and the mean DAS yields are shown in the last column. None of the *tri5*-deleted strains produced detectable amounts of DAS under conditions which induced high DAS levels in a wild type *Fusarium venenatum* strain #93  
 25 (BBA 64537, Biologische Bundesanstalt für Land- und Fortswirtschaft, Berlin, Germany).

Table 1. DAS production by single-spore isolates of LyMC4 and LyMC19

30	<i>F. venenatum</i> Strain	DAS yield			mean DAS yield
		(ppm)			(ppm)
		a.	b.	c.	

	#93	347	355	301	334
	A 3/5 <sup>1</sup>	36	15	91	47
	CC1-3	29	26	24	26
	JRoy36-19B	24	29	24	26
5	LyMC4	0	0	0	0
	LyMC4.B	0	0	0	0
	LyMC4.C	0	0	0	0
	LyMC19	0	0	0	0
	LyMC19.2	0	0	0	0
10	LyMC19.5	0	0	0	0

<sup>1</sup>*Fusarium venenatum* Quorn seed vial from Dr. Anthony Trinici, University of Manchester, Manchester, England.

#### 15 **Example 14: Fermentation of *Fusarium venenatum* LyMC4.B, LyMC4.C, LyMC19.2, and LyMC19.5**

20 Fermentations of *Fusarium venenatum* LyMC4.B, LyMC4.C, LyMC19.2, and LyMC19.5 were run at 30°C for 8 days in 2 liter fermentors containing medium composed per liter of 20 g of sucrose, 2.0 g of MgSO<sub>4</sub>·7H<sub>2</sub>O, 2.0 of KH<sub>2</sub>PO<sub>4</sub>, 2.0 of citric acid·H<sub>2</sub>O, 2.0 g of CaCl<sub>2</sub>·2H<sub>2</sub>O, 0.5 ml of AMG trace metals (pH adjusted to 4.5 prior to sterilization), and a filter sterilized mixture composed per liter of 2.5 g of urea and 30 ml of a soy vitamin mixture which was added after sterilization and cooling of the medium. Feed streams were batched autoclaved mixtures composed of sucrose and urea.

25 All of the single-spore isolates produced equivalent amounts of xylanase compared to a similar fermentation of *Fusarium venenatum* JRoy36-19B.

#### **Example 15: Construction of *Fusarium venenatum* N-2**

30 *Fusarium venenatum* strain N-2 was generated from the *Fusarium venenatum* CC1-3 morphological mutant by selection on potassium chlorate medium. The strain was confirmed to possess the *niaD* phenotype by its ability to grow on 1X Vogels medium supplemented with 2% glucose and 10 mM of either sodium nitrite, ammonium tartrate, hypoxanthine, or

uric acid, and its inability to grow on 1X Vogels medium supplemented with 2% glucose and 10 mM sodium nitrate.

#### Example 16: Construction of the *tri5* deletion construct pJRoy41

5 pJRoy40 was digested with *Bgl*II and the ends were filled in with the Klenow fragment according to Sambrook *et al.*, 1989, *supra*. The linearized vector was purified by 1% agarose gel electrophoresis using TAE buffer and agarase treatment. The vector was next treated with calf intestinal alkaline phosphatase according to Sambrook *et al.*, 1989, *supra*. The *nit3* gene of *Neurospora crassa* was removed from pNit3 (Fu and Marzluf, 1987, *supra*)  
10 by digestion with *Not*I and *Srf*I. The restriction reaction was treated with the Klenow fragment, and subjected to 1% agarose gel electrophoresis using TAE buffer. The 4886 bp fragment containing the *nit3* gene was isolated using agarase.

The *nit3* gene fragment was cloned into the filled in *Bgl*II site of pJRoy40 to create pJRoy41 (Figure 8). In this vector, the 3.7 kb fragment containing the *tri5* gene in the  
15 *Fusarium venenatum* genome was replaced with the 4.9 kb fragment containing the *Neurospora crassa nit3* gene.

#### Example 17: Transformation of *Fusarium venenatum* N-2 and analysis of transformants

20 Biomass for generation of protoplasts of *Fusarium venenatum* N-2 was prepared in 2 different ways. For batch 1, 50 ml of YEPG medium were inoculated with 5 agar plugs (1 cm) of *Fusarium venenatum* N-2, and cultured for 3 days at 26°C and 150 rpm. Ten ml of this culture were used to inoculate another 100 ml culture of YEPG, which was incubated at 200 rpm, 28°C for 20 hours before protoplasting. For preparation of Batch 2 protoplasts,  
25 agar plugs of *Fusarium venenatum* N-2 were inoculated into RA sporulation medium containing 0.1M Na<sub>2</sub>HPO<sub>4</sub> and 0.1 M NH<sub>4</sub>H<sub>2</sub>PO<sub>4</sub>, instead of sodium nitrate, plus 0.05% glucose. The culture was grown for 4 days at 28°C and 200 rpm. Fernbach flasks containing 500 ml of medium composed per liter of 10 g of succinic acid, 0.1 M NH<sub>4</sub>H<sub>2</sub>PO<sub>4</sub>, 0.1M K<sub>2</sub>HPO<sub>4</sub>, 1X COVE salts, and 0.5 g of glucose were inoculated with 10 ml of the first culture,  
30 and incubated for 65 hours at 26°C and 150 rpm. Approximately 10<sup>8</sup> spores were obtained from this culture. The spores were used to inoculate 50 ml of YEPG medium, which were

grown for 13.5 hours at 24°C and 150 rpm. Protoplasts were prepared as described in Example 6 and stored at -80°C.

Protoplasts of *Fusarium venenatum* N-2 were transformed with pJRoy41 (either uncut, linearized at the *Not*I site in the polylinker, or linearized at the *Nhe*I site in the 3' flank). Transformations were performed with pJRoy41 as described in Example 6, except that the reactions were plated onto empty 150 mm plates with 50 ml of (40°C) overlay medium containing 1X COVE salts, 0.8 M sucrose, 25 mM sodium nitrate, and 1% low melt agarose.

Four transformants were obtained from *Not*I digested pJRoy 41, 2 were obtained from *Nhe*I digested pJRoy 41, and 32 were obtained from undigested plasmid.

#### **Example 18: Genomic DNA preparation of putative *Fusarium venenatum tri5* deleted transformants**

Genomic DNA was prepared from the putative *Fusarium venenatum tri5* deleted transformants described in Example 17 using the following protocol. The transformants were grown in 25 ml of YEG medium for 72 hours at 30°C and 250 rpm. Mycelia were then collected by filtration through Miracloth and washed once with 25 ml of 10 mM Tris-1 mM EDTA (TE) buffer. Excess buffer was drained from the mycelia which were subsequently frozen in liquid nitrogen. The frozen mycelia were ground to a fine powder in an electric coffee grinder, and the powder was added to 20 ml of TE buffer and 5 ml of 20% w/v sodium dodecylsulfate (SDS) in a disposable plastic centrifuge tube. The mixture was gently inverted several times to insure mixing, and extracted twice with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v). Sodium acetate (3 M solution) was added to a final concentration of 0.3 M followed by addition of 2.5 volumes of ice cold ethanol to precipitate the nucleic acids. The nucleic acids were then pelleted by centrifuging the tube at 15,000 x g for 30 minutes. The pellet was allowed to air dry for 30 minutes before resuspension in 0.5 ml of TE buffer. DNase-free ribonuclease A was added to a concentration of 100 mg/ml and the mixture was incubated at 37°C for 30 minutes. Proteinase K was then added at a concentration of 200 mg/ml and the mixture was incubated an additional hour at 37°C. Finally, the mixture was extracted twice with phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v) before precipitating the DNA with

sodium acetate and ethanol as described earlier. The DNA pellet was dried under vacuum, resuspended in TE buffer, and stored at 4°C until further use.

#### Example 19: PCR screen for deletion of the *tri5* gene

5 A preliminary PCR screen was performed to test for deletion of the *tri5* gene in the transformants isolated in Example 17. The reaction was designed using primers that would amplify a 1.1 kb band from intact *tri5* DNA, but would fail to generate a band from DNA in which the *tri5* coding region had been replaced with the *nit3* gene. The PCR reaction was carried out with primers 551 5'-CGGTATCGAATGTACTCGAG-3' (*Tri5* bp 2524-2544) (SEQ ID NO. 16) and 510 5'-CCCATGGTGTGAACACC-3' (*tri5* bp 1397-1414) (SEQ ID NO. 17). The reaction contained 2.5 µl of DMSO, 1 µl of *Taq* DNA polymerase, 5 µl of 2.5 mM each of dATP, dCTP, dGTP, and dTTP, 5 µl of 10X PCR buffer, 0.5-1 µg of transformant genomic DNA (Example 18), 2 µl of each primer above at 50 pmol/µl, and the appropriate amount of water to obtain 50 µl. The reaction was performed using 1 cycle at 15 97°C for 5 minutes, 55°C for 1 minute, and 72°C for 1 minute, followed by 30 cycles each at 97°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute.

Transformants which failed to generate a 1.1 kb band corresponding to an intact *tri5* gene were cultured in liquid Vogels medium supplemented with 25 mM NaNO<sub>3</sub> and subjected to DAS analysis as described in Example 10. Several transformants produced no measurable levels of DAS under these growth conditions, while the positive control 20 consistently produced approximately 10 ppm DAS (Table 2).

Table 2. Summary of DAS and Southern analysis for putative *tri5* deletants

Strain	DAS (ppm)	<i>tri5</i> 5' probe	<i>tri5</i> orf probe
CC1-3	10	5.9	+
25 N2-119	ND	5.9	+
N2-1	ND*	7.1	-
N2-8	ND	7.1	-
N2-13	ND	7.1	-
N2-103	ND	7.1	-
30 N2-106	ND	7.1	-
N2-118	ND	7.1	NT**

N2-101	11	5.9, 7.1	+
N2-102	19	5.9, 7.1	+
N2-104	18	5.9, 7.1	+
N2-105	35	5.9, 7.1	+

\*ND: not detectable

\*\*ND: not tested

The strains which failed to generate a 1.1 kb band in the diagnostic PCR reaction were also subjected to Southern analysis. Putative *Fusarium venenatum tri5* deleted strain genomic DNA prepared as described in Example 18 was restriction digested with *DraI/SphI*.

The fragments were separated by electrophoresis on a 1% agarose gel using TAE buffer. DNA was transferred overnight to a Nytran Plus membrane using 5X SSC as the wicking buffer. The membrane was prehybridized for 2 hours at 65°C in DIG Easy Hyb. Hybridization was performed with the DIG-labeled “*tri5* flanking probe” (Example 9). Subsequently, the membrane was washed twice for 15 minutes each at room temperature in 2X SSC-0.1% SDS followed by two washes for 15 minutes each at 68°C in 0.1X SSC-0.1% SDS. The washed membrane was developed according to standard DIG protocol and exposed to Kodak X-OMAT AR film for approximately 1 hour at room temperature followed by development using a Konica QX-70 automatic film processor according to the manufacturer’s instructions.

Genomic DNA digested with *DraI/SphI* contained a 5932 bp hybridizing band in the wild type strain, and a 7100 bp hybridizing band in the deletion plasmid when the DIG-labeled “*tri5* flanking probe” was utilized. The 5.9 kb band corresponded to the wild type *tri5* gene, while the 7.1 kb band corresponded to DNA where the *nit3* gene had replaced the *tri5* gene. Several transformants produced two bands corresponding to both the intact *tri5* gene and to the deletion plasmid. In these strains, the deletion integrated ectopically, resulting in no deletion of the *tri5* gene. However, *Fusarium venenatum* transformants N2-1, N2-8, N2-113, N2-103, N2-106, and N2-118 each contained the single 7.1 kb band indicative of the deletion plasmid.

Genomic DNA from these putative deletants was also hybridized with the DIG-labeled “*tri5* open reading frame probe” (Example 9). In all but one case, the strains which displayed a single band indicative of the deletion plasmid during hybridization with the 5’

probe failed to contain a band which hybridized with the open reading frame probe of *tri5*. From Table 3, the majority of strains which were identified as *tri5* deletants by DAS analysis were identified as *tri5* deletants by Southern analysis. The data indicated that *Fusarium venenatum* strains N2-1, N2-8, N2-113, N2-103, and N2-106 were deleted in the *tri5* gene.

5

**Example 20: Generation of a *nit3* marker-free *tri5* deletion in *Fusarium venenatum* strain**

Removal of the *nit3* gene from the deletant *Fusarium venenatum* N2-8 was accomplished by transforming the strain with an *EcoRI* fragment containing the 5' and 3' flanking DNA from the deletion construct pJRoy40 (Example 7). Protoplasts and transformations were performed as described in Example 10. Transformation reactions were allowed to regenerate for 24 hours at room temperature after addition of 10 ml of YEPG medium supplemented with 0.8 M sucrose as osmoticum. The regenerated protoplasts were then concentrated and washed in sterile water by centrifugation (10 minutes, 2000 x g) and plated on potassium chlorate medium at a density of  $5 \times 10^6$  per ml. Several hundred colonies grew on the chlorate medium. One hundred of these colonies were analyzed based on their ability to grow on sodium nitrite, ammonium tartrate, hypoxanthine and uric acid, and their inability to grow on sodium nitrate. Approximately 50 *niaD* mutants were identified.

Twenty of these mutants were subjected to Southern analysis using the "*tri5* flanking probe" as described in Example 9. One transformant (N2-8-1) contained a band indicative of loss of the *nit3* gene. Southern hybridization was repeated with the *niaD* mutant (N2), the *nit3/tri5* replaced strain N2-8, and the putative excised strain N2-8-1. DNA from these strains was digested with *NheI* and *NruI* and probed with the "*tri5* flanking probe". The results showed the presence of a 6436 bp band in the N2 strain which was consistent with a wild type *tri5* gene, and the presence of a 7604 band in the *nit3/tri5* replaced strain N2-8 which was consistent with the replacement of the *tri5* gene with *nit3*. There was a decrease in size of the hybridizing band to 2718 bp in the excised strain N2-8-1 which was consistent with excision of the *nit3* gene.

30



### Example 21: Generation of an *amdS* marker-free *tri5* deletion in *Fusarium venenatum* strain MLY3

An unmarked *tri5* deletion in the genome of the *Fusarium venenatum* expression host MLY3 was generated as shown in Figure 9 by initially deleting the *tri5* gene and replacing it with the *amdS* gene flanked by repeated DNA sequences isolated from the upstream region of the *Aspergillus oryzae pyrG* gene (WO 98/12300). Isolates cured of the *amdS* gene were then selected by growth on plates containing fluoroacetamide.

Plasmid pLC31b was constructed by introducing direct repeats at the flanks of the *Aspergillus nidulans amdS* gene, and subcloning the resulting *amdS* cassette into the *tri5* deletion vector pJRoy40 (Example 5).

The initial step was the creation of pJRoy43, which is composed of pNEB193 (New England Biolabs) where the *PacI* and *XbaI* sites were replaced with a *SwaI* site. To accomplish this, a linker containing a *BamHI* site on the 5' end, a *SwaI* site in the middle, and a *SalI* site on the 3' end was created by annealing the following two oligos together:

5'-GATCGATTTAAAT-3' (SEQ ID NO. 18)

5'-TCGAATTTAAATC-3' (SEQ ID NO. 19)

The resulting linker was ligated into pNEB193, which had been digested with *BamHI* and *SalI*, to create pJRoy43.

Next, a 230 bp region upstream of the *Aspergillus oryzae pyrG* gene was chosen as a repeat sequence in *Fusarium venenatum*. This region was amplified as two different products from the *Aspergillus oryzae pyrG* plasmid pJaL335 (WO 98/12300) using the following two primer pairs, primers 3 and 4 and primers 5 and 6:

Primer 3: 5'-CGAATTTTCATATTTAAATGCCGACCAGCAGACGGCCCTCG-3' (SEQ ID NO. 20)

Primer 4: 5'-GCGATATCATGATCTCTCTGGTACTCTTCG-3' (SEQ ID NO. 21)

Primer 5: 5'-GCGATATCATCGACCAGCAGACGGCCCTCG-3' (SEQ ID NO. 22)

Primer 6: 5'-GCGTTTAAACATGATCTCTCTGGTACTCTTCG-3' (SEQ ID NO. 23)

The amplification reactions (50 µl) were prepared using approximately 40-50 ng of genomic DNA, prepared using the DNeasy Plant Mini Kit, as the template. Each reaction contained the following components: 40-50 ng of genomic DNA, 50 pmol each of the primers 3 and 4 or primers 5 and 6, 200 µM each of dATP, dCTP, dGTP, and dTTP, 1X *Taq*

DNA polymerase buffer, and 2.5 Units of *Taq* DNA polymerase. The reactions were incubated in a Perkin-Elmer Model 480 Thermal Cycler programmed as follows: Cycle 1 at 94°C for 2.5 minutes and 72°C for 2.5 minutes; cycles 2-26 each at 94°C for 45 seconds, 50°C for 45 seconds, and 72°C for 2 minutes; and cycle 27 at 94°C for 45 seconds, 50°C for 45 seconds, and 72°C for 10 minutes.

The reaction products were isolated on a 1% agarose gel where approximately 230 bp fragments were isolated. The first PCR product (approximately 230 bp fragment) contained a *SwaI* site at the 5' end and an *EcoRV* site at the 3' end while the second PCR product (approximately 230 bp fragment) contained an *EcoRV* site at the 5' end and a *PmeI* site at the 3' end. The two purified repeat fragments were first digested with *EcoRV* and ligated together. After purification (phenol-chloroform extraction and ethanol precipitation), the ligation product was then digested with *PmeI* and *SwaI* to produce approximately a 500 bp fragment which was purified by agarose gel electrophoresis and agarase treatment.

The resulting fragment was cloned into *PmeI* and *SwaI* digested pJRoy43 to create pJRoy44 (Figure 10). This vector contains the two 230 bp repeats separated by an *EcoRV* site and flanked by *SwaI* and *PmeI* sites.

An *EcoRI* fragment containing the *amdS* gene and regulatory region was isolated from a subclone of p3SR2 (Kelly and Hynes, 1985, *EMBO Journal* 4: 475-479), made blunt with the Klenow fragment, and ligated into *EcoRV* digested pJRoy44 to create pJRoy47 (Figure 11). This vector was digested with *PmeI* and *SwaI*, and the fragment containing the *amdS* gene flanked by the direct repeats described above was ligated into *BglII* digested, Klenow treated JRoy40 to create pLC31b (Figure 12) where the 3.7 kb fragment containing the *tri5* coding region had been replaced with the 3 kb fragment containing the *Aspergillus nidulans amdS* gene flanked by 230 bp repeats.

The resulting plasmid, pLC31b, was then digested with *EcoRI* and the 6.1 kb *EcoRI* fragment containing this *tri5* deletion cassette was gel purified using Qiaquick Gel Extraction Kit (Qiagen, Chatsworth, CA) prior to transformation.

*Fusarium venenatum* MLY3 protoplasts were prepared and then transformed as described in Example 6 with the gel-purified 6.1 kb *EcoRI* deletion fragment. Transformants were plated onto COVE plates to select for integration of the *amdS* gene. Replacement of the native *tri5* gene with the deletion cassette was confirmed by Southern hybridization in the 3

resulting transformants. Southern hybridizations were conducted using the Amersham (Arlington, IL) Vistra and Rapid Hyb protocols or the Boehringer Mannheim DIG System protocol provided by the manufacturer. Fungal genomic DNA of putative deletants was prepared using the DNeasy Plant Mini Kit (Qiagen Chatsworth, CA). Membranes were developed following the manufacturer's instructions and scanned using a STORM 860 (Molecular Dynamics, Sunnyvale, CA) for fluorescein-labeled probes or exposed to film for DIG-labeled probes. The "*tri5* flanking probe" hybridizes in the 5' flanking region 765 nts upstream of the *amdS* insertion.

All three transformants were sporulated and single spores were isolated using a micromanipulator. Three of the single-spore isolates of the three deleted transformants (9 total strains) were again sporulated. Selection for loss of the *amdS* marker occurred by spreading  $1 \times 10^6$  spores of the confirmed *tri5* deletants onto each of nine 150 mm plates containing fluoroacetamide medium. These plates were incubated at room temperature for up to 2 weeks. Resulting colonies were subcultured onto COVE plates and new fluoroacetamide plates. Colonies that grew well on fluoroacetamide and poorly or not at all on COVE were analyzed further. Of 308 isolates able to grow on fluoroacetamide (FA<sup>+</sup>), 3 were unable to grow on COVE (COVE<sup>-</sup>) and 1 grew very poorly on COVE but well on fluoroacetamide. Southern hybridization showed that the 3 COVE<sup>-</sup> strains still contained the *amdS* gene, while the one showing poor growth on COVE had a band corresponding to the predicted size of a "loop-out". This deletant, designated LyMC1, was sporulated and 3 isolates derived from single spores were obtained. The results of the Southern blots confirmed deletion of *tri5* and loss of the *amdS* gene in one transformant and in three spore-purified isolates derived from that transformant, LyMC1A, LyMC1B, and LyMC1C. Spores of all three transformants were generated as described in Example 6, except that Vogels nitrate medium was used and cultures were incubated for 72 hours at 24°C. Single spores were isolated using a micromanipulator.

Homologous recombination between the repeated sequences should result in deletion of the complete *amdS* gene. To confirm complete loss, the deletion region was PCR amplified using the following primers that hybridize to the 3' and 5' flanking regions of the *tri5* gene:

GAGa3.3: 5'-GGTAGCACGAGTGTCTGG-3' (SEQ ID NO. 24)

Tox5': 5'-AACTGGAAAGACCTGTGGGC-3' (SEQ ID NO. 12)

The amplification reactions (50 µl) were prepared using approximately 40-50 ng of genomic DNA of each deletant, prepared using the DNeasy Plant Mini Kit, as the template.

Each reaction contained the following components: 40-50 ng of genomic DNA, 50 pmol of the forward primer, 50 pmol of the reverse primer, 200 µM each of dATP, dCTP, dGTP, and dTTP, 1X *Taq* DNA polymerase buffer, and 2.5 Units of *Taq* DNA polymerase. The reactions were incubated in a Perkin-Elmer Model 480 Thermal Cycler programmed as follows: Cycle 1 at 94°C for 2.5 minutes and 72°C for 2.5 minutes; cycles 2-26 each at 94°C for 45 seconds, 50°C for 45 seconds, and 72°C for 2 minutes; and cycle 27 at 94°C for 45 seconds, 50°C for 45 seconds, and 72°C for 10 minutes.

The reaction products were isolated on a 1% agarose gel where a 990 bp product band was excised and cloned into pCR2.1 from the TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA) following the manufacturer's instructions, then used to transform One Shot TOP10 cells (Invitrogen, Carlsbad, CA). DNA was prepared from the resulting transformants using a Qiagen QIAprep-8 kit and analyzed by restriction digest using *Eco*RI. Plasmids were sequenced on an ABI PRISM 377 DNA Sequencer (ABI, Foster City, CA). PCR-amplification and sequencing of the deletion region demonstrated that a complete loop-out occurred and that only a single 230 bp repeat remained at the *tri5* locus. This repeat contained the 5' end of the 5' repeat and the 3' end of the 3' repeat, indicating that homologous recombination had occurred between the 2 repeats.

DAS production from the 3 spore-purified deletants, *Fusarium venenatum* MLY3, and wild type *Fusarium venenatum* strain BBA 64537 was determined as described in Example 10, except that Vogels nitrate medium was used to generate spores. Table 3 shows the DAS results from this analysis. None of three *tri5* deletants, LyMC1A, LyMC1B, or LyMC1C, produced any detectable DAS, while the wild type *Fusarium venenatum* strain BBA64537 and *Fusarium venenatum* MLY3 produced detectable amounts of DAS.

Table 3. DAS Analysis of *tri5* deleted *Fusarium venenatum* strains

Strain	DAS (ppm)* Mean of 3 values (+/-S.E.)
BBA 64537	318 (+/-31)
MLY3	29 (+/-11)

LyMC 1A <2  
LyMC 1B <2  
LyMC 1C <2

---

\*Detection limit 2ppm.

### Deposit of Biological Material

The following biological material has been deposited under the terms of the Budapest  
5 Treaty with the Agricultural Research Service Patent Culture Collection, Northern Regional  
Research Center (NRRL), Peoria, Illinois, and given the following accession numbers:

Deposit	Accession Number	Date of Deposit
<i>E. coli</i> DH5a pTri5	NRRL B-30029	May 6, 1998

10 The strain has been deposited under conditions that assure that access to the culture  
will be available during the pendency of this patent application to one determined by the  
Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. §1.14 and 35  
U.S.C. §122. The deposit represents a substantially pure culture of the deposited strain. The  
deposit is available as required by foreign patent laws in countries wherein counterparts of  
the subject application, or its progeny are filed. However, it should be understood that the  
15 availability of a deposit does not constitute a license to practice the subject invention in  
derogation of patent rights granted by governmental action.

20 The invention described and claimed herein is not to be limited in scope by the  
specific embodiments herein disclosed, since these embodiments are intended as illustrations  
of several aspects of the invention. Any equivalent embodiments are intended to be within  
the scope of this invention. Indeed, various modifications of the invention in addition to  
those shown and described herein will become apparent to those skilled in the art from the  
foregoing description. Such modifications are also intended to fall within the scope of the  
appended claims.

25 Various references are cited herein, the disclosures of which are incorporated by  
reference in their entireties.

## Claims

### What is claimed is:

- 5 1. A method for producing a polypeptide, comprising:
  - (a) cultivating a mutant of a parent filamentous fungal cell, wherein (i) the mutant comprises a first nucleic acid sequence encoding the polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a trichothecene under conditions conducive for the production of the polypeptide, and (ii) the  
10 mutant produces less of the trichothecene than the parent filamentous fungal cell when cultured under the same conditions; and
  - (b) isolating the polypeptide from the cultivation medium.
- 15 2. The method of claim 1, wherein the filamentous fungal cell is a an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Gibberella*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Myrothecium*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, or *Trichoderma* strain.
- 20 3. The method of claim 1, wherein the filamentous fungal cell is a *Fusarium* strain.
4. The method of claim 3, wherein the *Fusarium* cell is a *Fusarium venenatum* cell.
5. The method of claim 4, wherein the *Fusarium venenatum* cell is *Fusarium venenatum*  
25 ATCC 20334.
6. The method of claim 4, wherein the *Fusarium venenatum* cell is a morphological mutant.
- 30 7. The method of claim 6, wherein the *Fusarium venenatum* cell is a morphological mutant of *Fusarium venenatum* ATCC 20334.

8. The method of any of claims 1-7, wherein the gene is selected from the group consisting of *tri3*, *tri4*, *tri5*, *tri6*, *tril1*, *tril1*, *tril2*, and *tri101*.
- 5 9. The method of any of claims 1-8, wherein the gene is a *tri5* or trichodiene synthase gene.
10. The method of any of claims 1-9, wherein the gene is a *tri3* gene.
- 10 11. The method of any of claims 1-10, wherein the gene is a *tri4* gene.
12. The method of any of claims 1-11, wherein the gene is a *tri6* gene.
- 15 13. The method of any of claims 1-12, wherein the gene is a *tril1* gene.
14. The method of any of claims 1-13, wherein the gene is a *tril2* gene.
15. The method of any of claims 1-14, wherein the gene is a *tri101* gene.
- 20 16. The method of any of claims 1-15, wherein the mutant cell produces at least about 25% less of the trichothecene than the parent filamentous fungal cell when cultured under identical conditions.
17. The method of any of claims 1-16, wherein the mutant cell produces no trichothecene.
- 25 18. The method of any of claims 1-17, wherein the filamentous fungal cell comprises at least two copies of the first nucleic acid sequence.
19. The method of any of claims 1-18, wherein the heterologous polypeptide is a  
30 hormone, a hormone variant, an enzyme, a receptor or a portion thereof, an antibody or a portion thereof, or a reporter.

20. The method of claim 19, wherein the enzyme is an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase, or a ligase.

21. The method of claim 20, wherein the enzyme is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, a pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase.

22. The method of any of claims 1-21, wherein the mutant cell further comprises one or more modifications of one or more third nucleic acid sequences, wherein the modification reduces or eliminates expression of the one or more third nucleic acid sequences.

23. The method of claim 22, wherein the one or more third nucleic acid sequences independently encode an enzyme selected from the group consisting of an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, a pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.

24. The method of any of claims 22, wherein the one or more third nucleic acid sequences independently encode an aminopeptidase, carboxypeptidase, or protease.

25. The method of any of claims 1-24, wherein the second nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a trichothecene is not marked with a selectable marker.

26. A trichothecene-deficient mutant cell of a filamentous fungal cell, comprising a first



nucleic acid sequence encoding a heterologous polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes responsible for the production of a trichothecene, wherein the mutant produces less of the trichothecene than the parent filamentous fungal cell of the mutant cell when cultured under the same conditions.

5

27. The mutant cell of claim 26, wherein the filamentous fungal cell is a an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Gibberella*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Myrothecium*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*,  
10 *Thielavia*, *Tolypocladium*, or *Trichoderma* strain.

28. The mutant cell of claim 26, wherein the filamentous fungal cell is a *Fusarium* strain.

29. The mutant cell of claim 28, wherein the *Fusarium* cell is a *Fusarium venenatum* cell.

15

30. The mutant cell of claim 29, wherein the *Fusarium venenatum* cell is *Fusarium venenatum* ATCC 20334.

31. The mutant cell of claim 29, wherein the *Fusarium venenatum* cell is a morphological  
20 mutant.

32. The mutant cell of claim 31, wherein the *Fusarium venenatum* cell is a morphological mutant of *Fusarium venenatum* ATCC 20334.

25

33. The mutant cell of any of claims 26-32, wherein the gene is selected from the group consisting of *tri3*, *tri4*, *tri5*, *tri6*, *tri11*, *tri12*, and *tri101*.

34. The mutant cell of any of claims 26-33, wherein the gene is a *tri5* or trichodiene synthase gene.

30

35. The mutant cell of any of claims 26-34, wherein the gene is a *tri3* gene.

36. The mutant cell of any of claims 26-35, wherein the gene is a *tri4* gene.

37. The mutant cell of any of claims 26-36, wherein the gene is a *tri6* gene.

5

38. The mutant cell of any of claims 26-37, wherein the gene is a *tri11* gene.

39. The mutant cell of any of claims 26-38, wherein the gene is a *tri12* gene.

10 40. The mutant cell of any of claims 26-39, wherein the gene is a *tri101* gene.

41. The mutant cell of any of claims 26-40, wherein the mutant cell produces at least about 25% less of the trichothecene than the parent filamentous fungal cell when cultured under identical conditions.

15

42. The mutant cell of any of claims 26-41, wherein the mutant cell produces no trichothecene.

20

43. The mutant cell of any of claims 26-42, wherein the filamentous fungal cell comprises at least two copies of the first nucleic acid sequence.

25

44. The mutant cell of any of claims 26-43, wherein the heterologous polypeptide is a hormone, a hormone variant, an enzyme, a receptor or a portion thereof, an antibody or a portion thereof, or a reporter.

45. The mutant cell of claim 44, wherein the enzyme is an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase, or a ligase.

30

46. The mutant cell of claim 45, wherein the enzyme is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase,

glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, a pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase.

5 47. The mutant cell of any of claims 26-46, wherein the mutant cell further comprises one or more modifications of one or more third nucleic acid sequences, wherein the modification reduces or eliminates expression of the one or more third nucleic acid sequences.

10 48. The mutant cell of claim 27, wherein the one or more third nucleic acid sequences independently encode an enzyme selected from the group consisting of an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, a pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.

15 49. The mutant cell of claim 47, wherein the one or more third nucleic acid sequences independently encode an aminopeptidase, carboxypeptidase, or protease.

20 50. The mutant cell of any of claims 26-49, wherein the second nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a trichothecene is not marked with a selectable marker.

51. A method for obtaining the mutant cell of any of claims 26-50, comprising:

25 (a) introducing into a parent filamentous fungal cell a nucleic acid sequence comprising a modification of at least one of the genes responsible for the production of a trichothecene; and

(b) identifying the mutant from step (a), wherein the mutant produces less of the trichothecene than the parent filamentous fungal cell of the mutant cell when cultured under  
30 the same conditions.

52. An isolated trichodiene synthase obtained from a *Fusarium venenatum* strain, selected from the group consisting of:

(a) a trichodiene synthase having an amino acid sequence which has at least 97% identity with SEQ ID NO. 2;

5 (b) a variant of the trichodiene synthase having an amino acid sequence of SEQ ID NO. 2 comprising a substitution, deletion, and/or insertion of one or more amino acids;

(c) an allelic variant of (a) or (b); and

(d) a fragment of (a) or (c) that has trichodiene synthase activity.

10 53. The trichodiene synthase of claim 52, having an amino acid sequence which has at least 97% identity with SEQ ID NO. 2.

54. The trichodiene synthase of claim 52, comprising the amino acid sequence of SEQ ID NO. 2 or a fragment thereof.

15 55. The trichodiene synthase of claim 52, comprising the amino acid sequence of SEQ ID NO. 2.

20 56. The trichodiene synthase of any of claims 52-55, which is obtained from *Fusarium venenatum* ATCC 20334.

25 57. The trichodiene synthase of claim 52, which is encoded by the nucleic acid sequence contained in plasmid pTri5 contained in *E. coli* NRRL B-30029.

58. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the trichodiene synthase of any of claims 52-57.

59. A nucleic acid construct comprising the nucleic acid sequence of claim 58 operably linked to one or more control sequences which direct the production of the trichodiene synthase in a suitable expression host.

60. A recombinant expression vector comprising the nucleic acid construct of claim 59.

61. A recombinant host cell comprising the nucleic acid construct of claim 59.

5 62. A method for producing the trichodiene synthase of any of claims 52-57 comprising (a) cultivating a *Fusarium venenatum* strain to produce a supernatant comprising the trichodiene synthase; and (b) recovering the trichodiene synthase.

63. A method for producing the trichodiene synthase comprising (a) cultivating the host  
10 cell of claim 61 under conditions suitable for production of the trichodiene synthase; and (b) recovering the trichodiene synthase.

64. A method for obtaining a mutant cell, comprising:

15 (a) introducing into a parent cell, having a first nucleic acid sequence encoding a first gene product, a first nucleic acid construct comprising a nitrate reductase gene as a selectable marker and a modification of the first nucleic acid sequence, wherein the first construct incorporates into the genome of the parent cell replacing the endogenous first nucleic acid sequence with the modified first nucleic acid sequence resulting in reduced production of the first gene product compared to the parent cell when cultivated under the  
20 same conditions; and

(b) selecting a mutant cell from step (a) for the presence of the nitrate reductase gene and reduced production of the first gene product.

65. The method of claim 64, further comprising:

25 (c) selecting a mutant cell from step (b) under culturing conditions in which the nitrate reductase gene is deleted.

66. The method of claim 64, further comprising:

30 (c) introducing into the mutant cell from step (b) a second nucleic acid construct comprising a second nucleic acid sequence comprising 5' and 3' regions of the modified first nucleic acid sequence, but lacking the nitrate reductase gene, wherein the second construct

incorporates into the genome of the parent cell replacing the modified first nucleic acid sequence with the second nucleic acid sequence; and

(d) selecting a mutant cell from step (c) under culturing conditions in which the nitrate reductase gene is deleted.

5

67. A mutant cell obtained by the method of any of claims 64-66.

68. A method for producing a polypeptide, comprising:

10 (a) cultivating the mutant cell of claim 67 comprising a nucleic acid sequence encoding a polypeptide under conditions conducive for the production of the polypeptide; and

(b) isolating the polypeptide from the cultivation medium of the mutant cell.

15 69. A method for introducing an alteration into a target nucleic acid sequence contained in a cell, comprising:

20 (a) obtaining mutant cells of a parent cell by introducing into the parent cell a nucleic acid construct comprising a nitrate reductase selectable marker gene, flanked by nucleotide sequence repeats to form a marker cassette, wherein the repeats consist of a nucleotide sequence immediately 5' or a nucleotide sequence immediately 3' of the target DNA; and further wherein

when the flanking nucleotide sequence repeats consist of a nucleotide sequence 5' of the target DNA, the nucleic acid construct further comprises, 3' of, and contiguous to, the marker cassette, an additional nucleotide sequence consisting of a nucleotide sequence 3' of the target DNA sequence; and wherein

25 when the flanking nucleotide sequence repeats consist of a nucleotide sequence 3' of the target DNA, the nucleic acid construct further comprises, 5' of, and contiguous to, the marker cassette, an additional nucleotide sequence consisting of a nucleotide sequence 5' of the target DNA sequence;

30 (b) selecting mutant cells from step (a) by selecting for the presence of the nitrate reductase gene;

(c) cultivating the selected mutant cells under conditions effecting deletion of the

nitrate reductase gene by recombination between the flanking nucleotide sequence repeats;  
and

(d) selecting a mutant cell with an alteration in the target nucleic acid sequence in  
which the nitrate reductase gene has been deleted from the mutant cell.

5

70. A mutant cell obtained by the method of claim 69.

71. A method for producing a polypeptide, comprising:

(a) cultivating the mutant cell of claim 70 comprising a nucleic acid sequence  
10 encoding a polypeptide under conditions conducive for the production of the polypeptide;  
and

(b) isolating the polypeptide from the cultivation medium of the mutant cell.

20  
30  
40  
50  
60  
70  
80  
90  
100  
110  
120  
130  
140  
150  
160  
170  
180  
190  
200  
210  
220  
230  
240  
250  
260  
270  
280  
290  
300  
310  
320  
330  
340  
350  
360  
370  
380  
390  
400  
410  
420  
430  
440  
450  
460  
470  
480  
490  
500

## Abstract

The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a mutant of a parent filamentous fungal cell under conditions conducive for the production of the polypeptide, wherein (i) the mutant cell comprises a first nucleic acid sequence encoding the polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a trichothecene and (ii) the mutant produces less of the trichothecene than the parent filamentous fungal cell when cultured under the same conditions; and (b) isolating the polypeptide from the cultivation medium. The present invention also relates to mutants of filamentous fungal cells and methods for obtaining the mutant cells. The present invention also relates to isolated trichodiene synthases and isolated nucleic acid sequences encoding the trichodiene synthases. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the trichodiene synthases. The present invention further relates to mutants cells comprising a marker-free modification of a gene, and methods for obtaining and using such mutant cells.



# Lib 1

GAATTCTCTCAGTCGGCCTCATCTGGCAGGTGCTAATATATTCTA 45  
 CCCGCGCTTGGCTACCTATGCCACACACAAAGCTTCATGTTTGGT 90  
 TCATATCGTATACTCGCTTCAACAGTTCTGCGGGTACGACTCTCG 135  
 TATGGATGTAATAAACAAATGTTCCGACCTATTATGCCGAGTTAC 180  
 CGTGGACAATTATCGGGCCGAAAAGAATGCATTTGTGAATTGTA 225  
 ATCCTGCCTGTTTGTGGAGTGATAAGTGACATATTGGAAAAGTCG 270  
 TCAAGCAATTGGAGGTTTCATCAACTGTGGAGTCATCGTTTGGG 315  
 CAAACAATACTATGTAGGGTAGGCTTCTGCTGCAGCATCAATGAC 360  
 TCGTTTGGATCGAGTCCTTTTGTGTTGCCAAGGCGTATGGGGCCTGC 405  
 AGGGAACGAGTCAGTCGTATCAGGCCGGTGAGGCAAATGCCGTTT 450  
 CGCAGCAGCTATCATTTGTGCGGGGATTTTCGCGAAGCTTTGCGT 495  
 GACGAGTCAAATCCGCACATCTTGATTTCATGAGTTGTTGAATTTA 540  
 GCTGTTTCATTTCGTGAGTGGCTAAAGCGTATCTAGTCGATTGTCAA 585  
 ATTCAGACTTGACAGGTCCCTTGATGAATGAGACGTCGGATGTCC 630  
 CTAGCCGAGATGCGGATTGTGACAACGGAAGAGACAGGGGCAGGG 675  
 TTCATGGGTGTTGAACCTTGTTCACTGAAACGGTGATGTCCTTGG 720  
 TCTACAAAGTATCCTTCACATGTCTCTGTTCCAGACCACGTGGT 765  
 TATTCTGGCATCCGGGTCCCTATTGATTGGCTGATTTCTTGCACTG 810  
 ATACATACAAATAAGTCCAAGACTGTATTCTACTGGCAAATTAT 855  
 GCCGACAAGGGGAAATCATTTCTGAATTAGTGATGAAGCATGCCGT 900  
 CGAAGCCGAAGAGAACTTTGCGCAGCAACTGGAAAGACCTGTGG 945  
 GCTGTAGAGCGCACAGCACGGTAGTAAGACCTACGGCCCTGGTAT 990  
 CATGGTTGTAGCCTCTTCCGTATTGCTCACATATCCACCGGTTTT 1035  
 CTACATAAACAGTCTGAGTCCTGATAGTGGATATTATATCTTCCA 1080  
 GGACCTAGTCTAGGTAGTAGTCGGCATTGTGAAACGCCTAGTGGCA 1125  
 AGAGATCGCTTAGCCTCCAGCCTGGCAATATCGCGGCTTCCTCAG 1170  
 GTTGTACCACGAATGATGATCTCAATTGTGCTTCCCCTGTCGTGA 1215  
 ATTTGCTAGTGCGACGGGACTTGCCAGGCTTACGGCACCTACAAG 1260  
 TCGCGCCAGCCTTCTGACAGTGATTGTATGCAAGATCGTCATTAG 1305  
 TTATGATTAAGCTTTGATAAACAAGAGCGCCACAGCCTTTCTTTA 1350  
 ACTCCGACAACCTCAACGGTGACATGCATACCGCGTGACACTATT 1395  
 TCCCATGGTGTGAACACCATCAATGACTTAGAGTAGATAACCACT 1440  
 TGAAACTTCTAGAAATGTCCAAGAACTACACTCAGTGTTTCATA 1485  
 GAACTAAGACAATGTTTCATTGAAGGATGGGATTTGAGACTCCGTA 1530  
 CTGCTTCACCTCGGAAAATAAGCACTGTTTAGCACCCGTTAAGCC 1575  
 AAGTCCTTCAAACGTGGGGACGGATTTAACCAACAGCAGAGTGGA 1620  
 TAAGCCTGTACTCTACTCATTGAATGTATATAATACATTGCTAGG 1665  
 TACATACGCAGCTTTCAGGCACAGATAACGAAGATCTTAGGGTAG 1710  
 ATTCCAAAACATCGGAAGGGGTACAGATCGCACTAGCTACTATG 1755  
 CCATCCAGAGCCTCTTGCTAACCAAACAGAGCTAAGTCGCTTAAC 1800

Fig. 2A

CCTTATTCAAAGAACACAGTTGTATTGTGCATCCGGGATCTAACT 1845  
 GTCTTGGACAAGCGTGTCTGTATCCGTAAACGGCTGGTGGTTTTG 1890  
 TAGGGTATGATAGAATGGTTGCACTTAAGGCCTGTCGACTAGGTA 1935  
 AGCTTTTCCCAGGGAAGAATAAAACACCGCGGCTGCTTAGACAAG 1980  
 TGAGGCTTTCTTCTCCGTCAACAACTGCCGTCTCACTAGTCCAA 2025  
 ACTTGGTACACGGACAACAGCCGAACCTCAAACATTTAGCCTCAGGA 2070  
 TTCATCCCTAGCTTTAGGCCTACTCCTCGTCCCTTGACACCGGGA 2115  
 TGTAGTTCCTATCGCTTGCGTAGCTCTTTACTGCATGTGCCGAGC 2160  
 TAAAGATAAAATCGGACTAAAGATTTCGTTCCGGGAGCCGAATGCT 2205  
 TTCTCAAGCTCGTCGTGTTGCAGGGGATGGAAGACCTCCAGCGTA 2250  
 CGTCACGGTCTCTATCACTACGAATTTGCTGGGAAGGCTATTTGC 2295  
 ATTAATGTCAAGTCAATTATTAGGCCTAACAACACAAGTTTAACT 2340  
 AAAGATTGTGGATGGTTGACATTTGCCATATGTTGATATATAGTT 2385  
 GATAGCAACAGCACTTTGCAATAGGACAATAATAGCGACTTGACT 2430  
 TGAAAATTTCGCAAAGAACTGTTATAAATCATTATACCATTATCAT 2475  
 CATGGAGAACCTTCCCCTGAGTATTTTCTCAACACTTCTGTGCG 2520  
 M E N F P T E Y F L N T S V R  
 CCTTCTCGAGTACATTCGATACCGAGATAGCAATTATACCCGGGA 2565  
 L L E Y I R Y R D S N Y T R E  
 AGAGCGTATCGAGAATTTGCACTATGCTTACAACAAGGCTGCTCA 2610  
 E R I E N L H Y A Y N K A A H  
 TCACTTTGCTCAGCCACGACAACAGCAGCTGCTCAAGGTAGACCC 2655  
 H F A Q P R Q Q Q L L K V D P  
 TAAGCGACTACAGGCTTCCCTCCAACTATTGTTGGCATGGTGGT 2700  
 K R L Q A S L Q T I V G M V V  
 ATACAGTTGGGCAAAGGTCTCCAAAGAGTGTATGGCGGATCTATC 2745  
 Y S W A K V S K E C M A D L S  
 TATTCATTACACGTACACACTCGTTTTTGGATGACAGCAGCGATGA 2790  
 I H Y T Y T L V L D D S S D D  
 TCCGTATCCAGCCATGATGAACCTATTTCAACGATCTTCAGGCTGG 2835  
 P Y P A M M N Y F N D L Q A G  
 ACGAGAACAGGCCACCCATGGTGGGCGCTTGTTAATGAGCACTT 2880  
 R E Q A H P W W A L V N E H F  
 TCCCAATGTCCTTCGACATTTTGGTCCCTTCTGCTCATTTGAACCT 2925  
 P N V L R H F G P F C S L N L  
 TATCCGCAGCACTCTTGACTGTAAGTACCCTGGCTCTATTATTTTC 2970  
 I R S T L D  
 ACCGCCTTAATAAGCTAACAGTGATGGAATTATAGTTTTTTGAGGG 3015  
 F F E G

Fig. 2B

ATGCTGGATCGAGCAGTACAACCTTTGGAGGATTTCCAGGATCTCA 3060  
 C W I E Q Y N F G G F P G S H  
 TGACTATCCTCAGTTTCTTCGACGCATGAATGGCTTGGGTCAGT 3105  
 D Y P Q F L R R M N G L G H C  
 TGTCGGGGCTTCTTTGTGGCCCAAAGAGCAGTTTGATGAGAGAGG 3150  
 V G A S L W P K E Q F D E R G  
 TCTATTCCTTGAAATCACATCAGCCATTGCTCAGATGGAGAACTG 3195  
 L F L E I T S A I A Q M E N W  
 GATGGTCTGGGTCAATGATCTCATGTCTTTCTACAAGGAGTTCTGA 3240  
 M V W V N D L M S F Y K E F D  
 TGATGAGCGTGACCAGATCAGTCTCGTCAAGAACTACGTCGTCTC 3285  
 D E R D Q I S L V K N Y V V S  
 TGATGAGATCACTCTCCACGAAGCTTTAGAGAAGCTCACCCAGGA 3330  
 D E I T L H E A L E K L T Q D  
 CACTCTACACTCGTCCAAGCAGATGGTAGCTGTCTTCTCTGACAA 3375  
 T L H S S K Q M V A V F S D K  
 GGACCCTCAGGTGATGGACACGATTGAGTGCTTCATGCACGGCTA 3420  
 D P Q V M D T I E C F M H G Y  
 TGTACGCTGGCACTTGTGCGATCACAGGTACCGTCTGAATGAGAT 3465  
 V T W H L C D H R Y R L N E I  
 CTACGAAAAGGTCAAAGGACAAAAGACCGAGGACGCTCAGAAGTT 3510  
 Y E K V K G Q K T E D A Q K F  
 CTGCAAGTTCTATGAGCAGGCTGCTAACGTCGGAGCCGTTTCGCC 3555  
 C K F Y E Q A A N V G A V S P  
 CTCGGAGTGGGCTTATCCACCTATTGCGCAACTGGCAAACATTCTG 3600  
 S E W A Y P P I A Q L A N I R  
 GTCCAAGGATGTGAAGGATGTGAAGGATGTGAAGGAGATTTCAGAA 3645  
 S K D V K D V K D V K E I Q K  
 GCCTCTGCTGAGCTCAATTGAGCTAGTGGAATGACCGACGGTGAG 3690  
 P L L S S I E L V E .  
 ATGGAAGTATGTTTTGCGGGTACTCGCTAGGAGAATACTGGTCGT 3735  
 TTATCATGATTACAAATAGCTTGGTTATGTTTTTATTAGCATTTA 3780  
 CAGTTGAACAAGGATAATTACTACTGAATAGGCAGCTGAAACTGA 3825  
 TGTCTGTAACCTCCAGCCTGTTATTCCACTTGCCTGCAGGTCTTTG 3870  
 CATGGCCAAGTCATACATACCTGTTACGGTGTGGTGCGACAGGG 3915  
 CTATCCATACCCCGGCCAGCCTGCAGTAGAGCAGGCGTCACGGC 3960  
 CTGTAGTGCGCTGCGGGAATCTTCCACCCGTTTCGGATGTGGGAAG 4005  
 TTTTGTGTGCTCCTCGGGGCTAACACATTCCAACCATTAATTGATCT 4050  
 TCAAAACGCTTGCAATTTGCTCTATATGGCCGGCCTTGATCCTTGT 4095  
 ATATTTTACCATCTGACATTTTCTGCACAAGGCGTACAGAAACC 4140

Fig. 2C

ACACGAGGTAAAGTTTCATGGCCGCTTGGCCACTATTGGAAACAC 4185  
GACACACATGTTAAACTCTATCCTTGCATTATATTGTAACATCGC 4230  
CTAACATCTCCACGCACTATTCCTTTGCGTTCCTTATTCATCCTC 4275  
AACTGTATGCCAACCAACAATCATCAAATTATTATTGCAGTTAGT 4320  
CATCATGGATTTCCCAAAGCCGAGGCAGGTTAGAGAGACGAGCCT 4365  
GTTGATGTACTACCTGGACGTCGTGTTTTCTCTACAATGCATTAC 4410  
CCCAAACAACAATTGTCTGGGCAAGAGAGAGTGGCTGTTGACTAT 4455  
ACTAACCTCTGCTCGGCCTACGTACTATGCAACATTGTGCCTGGC 4500  
CCTCCTTTATAAAGAATCCCTCTCAAGCCCTTGCAGAGCCGAACA 4545  
AGCGGTAGTATGGAAGAGAGAAAAGACCTACTACTACATTCTTGC 4590  
GCTCCAAGAGTCTCAGAAGCTGTTGGGTGGACTCGACAAGACTTT 4635  
TGGTATCACAAGGCTGAAGGGGACCGTCGTTGCCCTTGCTTGCAT 4680  
GATCCAGCTCATCGGGTTTGAGGTAAGACGAATCCACAACGCTCA 4725  
CAATGTTCAATACCCGATCTATAATTATCATTGGAGACTAACGCA 4770  
TTTGGACAGTCTTCGCACTTAAGTAGGGGAGATTGGCGCGTTCAC 4815  
CTCCTTGCAGCCAACACACTCATTCTGTGTTGGTCGAGGGTTGG 4860  
TCCACAGCTTTGCAATCAGGCCCTCCAGCCACTTCAATCTGGTGT 4905  
GAGTTGGATGATTTCGGATTTTCGGCTCAACTGAAGATCAAATTC 4950  
TTGAGCTTCGAATATCTTGGTGCTTTGAGATTCTTGTCAAACCTC 4995  
CTGGCGACAACCGGTATCTTATCGTGCATATCTGTTGGCCCATCA 5040  
GCACCATTCGAAGATTATGGTCACTCTTAGACCAGCCAGGCCTC 5085  
ATACAGATGGATGAGGTGCTAGGGTGCAAGAACTGGGCCATGCTG 5130  
ACTATACTCGAAGTGGGTAAGCTGGACCGGTGGAAGCGCCAGGAG 5175  
CAAGAGCACAACCGTTTGAGCCTAAAGACACTCGCTAGGCGTGCA 5220  
ATGATGATAGAGGACATGTTGACAGACGAGCTACAAAAGCTTCCG 5265  
GCAAGCGAGACACTGCCTGATCTCATCAACCATATTTACGCCGCC 5310  
TCCATTATGACATACCTGCATACAGTAGTTTCAGGACTCAATCCC 5355  
AACCTTTCAGAGGTCCAGGATAGTGTGAACGCAACGATTCTATTG 5400  
TTGGAGAGACTCCCAGATCTGCAAGCTGTGCGCTCTGTTACTTGG 5445  
CCTTTGGCTGTACAGGTTGCATGGCCTCGGAAAGTCATAAGGAC 5490  
TTTTTTCAGAAATACTCTGAGGTCTATGACGCGACATTCACCTCG 5535  
TTAAAAAAGTATGATGGAACCTTTGAGGTTTTTGAAGACGCTTGG 5580  
AACAAACGAGAGATAGACAGAGAGTCTCCAATCAGGTGGGAGGAT 5625  
CTGATGGATCACCATGGGCTTCCAGTGCTCCTACTCTAGGGTTGG 5670  
TATCATCCCCAGACACTCGTGCTACCAACACAGAGACTGTCTTTA 5715  
GTCTTTATTTTGCATACGCTACCTGATTCATGTAAGTTCGGTGTT 5760  
CACTTGCCGACGATACATCCAGGGAAGTCTGACTAGTCAGTGCTT 5805  
ATGGTTCGATTCTTTTGGCGTTATAAACCGGTTCTGTCTATGAAG 5850  
CAAGATATGATTTTCGATGAGAGGGAAGAGCGAACAACCTATTCACA 5895  
TGTAACCTAAATTATAGACTTTTCAGTATAAACTTTTCGATTATAAG 5940

Fig. 2D

CCACACCTAATCTAAGTATATATATCCAATCAATTGTACCAAAAG 5985  
 TAGTCTGGAATCATGGTTGTCAATCGGTGCTGTGTTCCCTCCATAT 6030  
 TCTTGACATGATTTGACTTGTCCGGTCCGCGCGACACACGATGTT 6075  
 GATCATAATGAAGGAGTGTTGATTTTGAGTAGGAAAAGATATTGC 6120  
 AGTTCCTTGTAAGATCGTTCGGAACGAAACCCGGCTGGAGTATG 6165  
 ATTTGTTTCGTGGACCCGAAGTGCAAAAATGCCGGAATTAATGACA 6210  
 GGCATTCTCTTCAGTTGGCTTGGGTTGAGATATTGGTCTGCGTCT 6255  
 GTTGGAAGCTGACATTGGATCTTCAACATGCTTTTGCCGCGACC 6300  
 CAGATGGTTGCGCATAAGGCAGCGCTGACTCCCGAGTATGCGAAA 6345  
 ACCTCGAGCCACGAAACATCAGGGTCCATTTCCGTTGAGTCGATC 6390  
 AATTTAGCGGCTGCGAGCATCTTGAGAGTTTTGGGATAAGTCTTT 6435  
 GAGTGGACAACAGTAATGTGATATGGTATGATCTGATGTCGTGTT 6480  
 CGTGTTGATGAGAATAAATTGTTGAGCTGATTCCCATCGGCTCTG 6525  
 ACCAACAGTTAATATCTAAATTCTTCTACTATCTATGCACTATGG 6570  
 ACTGGGGAGTCAACGTTGTTTCGTTCTCTGGAGAGAGGCCTAAATG 6615  
 ATCTTGAATTGGTGTGTAAGTCAAACGTCAGTAGAAGGCCTGAAT 6660  
 TCGCAAGCGCCGAACTTCCGGCCTACACTGCCACTGACTTTGCGG 6705  
 CTCAGCATTTAGATAGTGGGCTTCACAGCGGGTATTGTCTCTTCT 6750  
 GCAGCATTGCTACGGATTTATCGGCTTCAACAACCCTTGCTGAAC 6795  
 CAATGATGGGTTACATTGATGGGCATTCGTTTTTAACTTTTGTC 6840  
 AGGTTGGCAGAGGCCTAAAATCTGCCGTCGGTGTGTGAGAGACCA 6885  
 TGAATCAGGCCCTGCATTAATGTAGGGCATTTGCTAGCCCGCGG 6930  
 CAAGAGCGCAGAAAGC 6946

Fig. 2E




Fig. 3




Fig. 4






Fig. 5




Fig. 6




Fig. 7

**pJRoy40**  
(7535 bp)

*tri5* 3'

*tri5* 5'

NotI, NheI, EcoRI, BglII

**pJRoy41**  
(12405 bp)

*tri5* 3'

*tri5* 5'

*nit3*

NotI, NheI, EcoRI

**pBluescriptKS(-)Nit3**  
(7799 bp)

*nit3*

NotI, SrfI, EcoRI

**nit3**  
(4881 bp)


*nit3*

BglII, Klenow


SrfI/NotI, Klenow

Fig. 8

Wild type *tri5* region



*tri5* deletion and replacement  
with the *amdS* marker



*amdS* loop-out



deletion with single repeat

Fig. 9




Fig. 10




Fig. 11




Fig. 12



As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Methods For Producing Heterologous Polypeptides in Trichothecene-Deficient Filamentous Fungal Mutant Cells

the specification of which (check only one item below):

☐ is attached hereto

☒ was filed as United States application

Application No. to be assigned

on May 20, 1999

and was amended

on \_\_\_\_\_

☐ was filed as PCT international application

Number \_\_\_\_\_

on \_\_\_\_\_

and was amended under PCT Article 19

on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 of any provisional or foreign applications(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign applications(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR U.S. PROVISIONAL/FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY		DATE OF FILING	PRIORITY CLAIMED
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**  
(Includes Reference to PCT International Applications)

Attorney's Docket Number:

5563.200-US

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this applications is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:**

U.S. APPLICATIONS		STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	Patented	Pending	Abandoned
09/082,217	May 20, 1998		X	
PCT APPLICATIONS DESIGNATING THE U.S.				
APPLICATION NO.	FILING DATE	US SERIAL NUMBERS ASSIGNED (if any)		

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Steve T. Zelson    Elias J. Lambiris    Valeta A. Gregg    Carol E. Rozek    Robert L. Starnes    Reza Green  
Reg. No. 30,335    Reg. No. 33,728    Reg. No. 35,127    Reg. No. 36,993    Reg. No. 41,324    38,475

**Send Correspondence to:** Steve T. Zelson, Esq.  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, New York 10174-6400







**Direct Telephone Calls To:**

Steve T. Zelson  
(212) 867-0123

1	Full Name of Inventor	Family Name Royer	First Given Name John	Second Given Name C.
	Residence & Citizenship	City Davis	State or Foreign Country California	Country of Citizenship US
	Post Office Address	Post Office Address 3320 Seabright Avenue	City Davis	State & Zip Code/Country CA 95616/US
2	Full Name of Inventor	Family Name Christianson	First Given Name Lynne	Second Given Name M.
	Residence & Citizenship	City Davis	State or Foreign Country California	Country of Citizenship US
	Post Office Address	Post Office Address 722 Barcelona Avenue	City Davis	State & Zip Code/Country CA 95616/US
3	Full Name of Inventor	Family Name Gambetta	First Given Name Gregory	Second Given Name A.
	Residence & Citizenship	City San Carlos	State or Foreign Country California	Country of Citizenship US

	Post Office Address	Post Office Address	City	State & Zip Code/Country
	Address	3294 La Mesa Drive	San Carlos	CA 94070/US
4	Full Name of Inventor	Family Name	First Given Name	Second Given Name
		Brody	Howard	
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
		Davis	California	US
	Post Office Address	Post Office Address	City	State & Zip Code/Country
		2415 El Cemente Avenue	Davis	CA 95616/US
5	Full Name of Inventor	Family Name	First Given Name	Second Given Name
		Otani	Suzanne	M.
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
		Elk Grove	California	US
	Post Office Address	Post Office Address	City	State & Zip Code/Country
		6013 Villa Rosa Way	Elk Grove	CA 95758/US
6	Full Name of Inventor	Family Name	First Given Name	Second Given Name
		Yoder	Wendy	T.
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
		Winters	California	Great Britain
	Post Office Address	Post Office Address	City	State & Zip Code/Country
		8503 Pleasants Valley Rd.	Winters	CA 95694/US

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
		
Date	Date	Date
6-8-99	5-24-99	6/14/99
Signature of Inventor 4	Signature of Inventor 5	Signature of Inventor 6
6-8-99		
Date	Date	Date
	5/24/99	5/25/99

# SEQUENCE LISTING

<110> John C. Royer  
Lynne M. Christianson  
Gregory A. Gambetta  
Howard Brody  
Suzanne M. Otani  
Wendy T. Yoder

<120> Methods For Producing Heterologous  
Polypeptides In Trichothecene-Deficient Filamentous Fungal  
Mutant Cells

<130> 5563.200-US

<140> To Be Assigned

<141> 1999-05-20

<150> 09/082,217

<151> 1998-05-20

<160> 24

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 6946

<212> DNA

<213> Fusarium

<400> 1

gaattctctc	agtcggcctc	atctggcagg	tgctaataata	ttctacccgc	gcttggctac	60
ctatgccaca	cacaaagctt	catgtttggg	tcataatcgta	tactcgcttc	aacagttctg	120
cgggtacgac	tctcgatg	atgtaataaa	caaagtgtcc	gacctattat	gccgagttac	180
cgtggacaat	tatcggggccg	gaaaagaatg	catttgtgaa	ttgtaatcct	gcctgtttgt	240
ggagtgataa	gtgacatatt	ggaaaagtcg	tcaagcaatt	ggaggtttca	tcaactgtgg	300
agtcacgtt	ttgggcaaac	aatactatgt	agggtaggct	tctgctgcag	catcaatgac	360
tgttttggat	cgagtccttt	tggtgccaa	gcgtatgggg	cctgcaggga	acgagtcagt	420
cgtatcaggc	cggtgaggca	aatgccgttt	cgcagcagct	atcatttgtc	gcgggatttt	480
cgcgaagctt	tgcgtgacga	gtcaaaccg	cacatcttga	ttcatgagtt	gttgaattta	540
gctgttcat	cgtgagtggc	taaagcgtat	ctagtcgatt	gtcaaattca	gacttgacag	600
gtcccttgat	gaatgagacg	tcggatgtcc	ctagccgaga	tgccgattgt	gacaacggaa	660
gagacagggg	cagggttcat	gggtgttgaa	ccttgttcac	tgaaacggtg	atgtctttgg	720
tctacaaagt	atccttcaca	tgtctctgtt	cccagaccac	gtggttattc	tggcatccgg	780
gtcctattga	ttggctgatt	tcttgactg	atacatacaa	ataagtccaa	gactgtattc	840
tactggcaaa	attatgccga	caaggggaaa	tcattctgaa	ttagtgatga	agcatgccgt	900
cgaagccgaa	gagaaacttt	gcgcagcaac	tggaaagacc	tgtgggctgt	agagcgcaca	960
gcacggtagt	aagacctacg	gccctggtat	catggttgta	gcctcttccg	tattgctcac	1020
atatccaccg	gtttttctaca	taaacagtct	gagtcctgat	agtggatatt	atatcttcca	1080
ggacctagtc	taggtagtag	tcggcatttg	aaacgcctag	tggcaagaga	tcgcttagcc	1140
tccagcctgg	caatatcgcg	gcttcctcag	gttgtaaccac	gaatgatgat	ctcaattgtg	1200
cttccctgt	cgtgaatttg	ctagtgcgac	gggacttgcc	aggcttacgg	cacctacaag	1260
tcgcgccagc	cttctgacag	tgattgtatg	caagatcgct	attagttatg	attaagcttt	1320
gataaacaag	agcgccacag	cctttcttta	actccgacaa	cctcaacggt	gacatgcata	1380
ccgcgtgaca	ctatttccca	tggtgtgaac	accatcaatg	acttagagta	gataaccact	1440
tgaaacttct	agaaatgtcc	aagaaactac	actcagtgtt	tcatagaact	aagacaatgt	1500
tcattgaagg	atgggatttg	agactccgta	ctgcttcacc	tcggaaaata	agcactgttt	1560
agcaccctgt	aagccaagtc	cttcaaactg	ggggacggat	ttaaccaaca	gcagagtggg	1620

taagcctgta	ctctactcat	tgaatgtata	taatacattg	ctaggtagat	acgcagcttt	1680
caggcacaga	taacgaagat	cttagggtag	attccaaaac	atcggaaggg	gtcacagatc	1740
gcactagcta	ctatgccatc	cagagcctct	tgctaaccaa	acagagctaa	gtcgcttaac	1800
ccttattcaa	agaacacagt	tgtattgtgc	atccgggatc	taactgtctt	ggacaagcgt	1860
gttctgtatc	cgtaacggct	ggtaggtttg	tagggtagta	tagaatgggt	gcacttaagg	1920
cctgtcgact	aggtaagctt	ttcccaggga	agaataaaac	accgcggctg	cttagacaag	1980
tgaggctttc	ttctccgtca	acaaactgcc	gtctcactag	tccaaacttg	gtcacggaca	2040
acagccgaac	tcaaacattt	agcctcagga	ttcatcccta	gctttaggcc	tactcctcgt	2100
cccttgacac	cgggatgtag	ttcctatcgc	ttgcgtagct	ctttactgca	tgtgccgagc	2160
taaagataaa	atcggactaa	agattcgttc	cgggagccga	atgctttctc	aagctcgtcg	2220
tgttgagggg	gatggaagac	ctccagcgta	cgtcacgggc	tctatcacta	cgaatttgct	2280
gggaaggcta	tttgcattaa	tgtcaagtca	attattaggc	ctaacaacac	aagttttaact	2340
aaagattgtg	gatgggtgac	atttgccata	tggtgatata	tagttgatag	caacagcact	2400
ttgcaatagg	acaataatag	cgacttgact	tgaaaattcg	caaagaactg	ttataaatca	2460
ttataccatt	atcatcatgg	agaactttcc	cactgagtat	tttctcaaca	cttctgtgcg	2520
ccttctcgag	tacattcgat	accgagatag	caattataacc	cgggaagagc	gtatcgagaa	2580
tttgacttat	gcttacaaca	aggctgctca	tcactttgct	cagccacgac	aacagcagct	2640
gctcaaggta	gaccctaagc	gactacaggc	ttccctccaa	actattgttg	gcatgggtgg	2700
atacagttgg	gcaaaggctc	ccaaagagtg	tatggcggat	ctatctattc	attacacgta	2760
cacactcggt	ttggatgaca	gcagcgatga	tccgtatcca	gccatgatga	actatttcaa	2820
cgatcttcag	gctggacgag	aacaggccca	cccatgggtg	gcgcttggtt	atgagcactt	2880
tccaatgtc	cttcgacatt	ttggtccctt	ctgctcattg	aaccttatcc	gcagcactct	2940
tgactgtaag	taccctggct	ctattatttc	accgccttaa	taagctaaca	gtgatggaa	3000
tatagttttt	gagggatgct	ggatcgagca	gtacaacttt	ggaggatttc	caggatctca	3060
tgactatcct	cagtttcttc	gacgcatgaa	tggtctgggt	cactgtgtcg	gggcttcttt	3120
gtggcccaaa	gagcagtttg	atgagagagg	tctattcctt	gaaatcacat	cagccattgc	3180
tcagatggag	aactggatgg	tctgggtcaa	tgatctcatg	tctttctaca	aggagtccga	3240
tgatgagcgt	gaccagatca	gtctcgtaaa	gaactacgct	gtctctgatg	agatcactct	3300
ccacgaagct	ttagagaagc	taccacagga	cactctacac	tcttccaagc	agatggtagc	3360
tgtcttctct	gacaaggacc	ctcaggtgat	ggacacgatt	gagtgcctca	tgcaaggcta	3420
tgtcacgtgg	cacttgtgcg	atcacaggta	ccgtctgaat	gagatctacg	aaaaggtaaa	3480
aggacaaaag	accgaggacg	ctcagaagtt	ctgcaagttc	tatgagcagg	ctgctaacgt	3540
cggagccggt	tgcacctcgg	agtgggctta	tccacctatt	gcgcaactgg	caaacattcg	3600
gtccaaggat	gtgaaggatg	tgaaggatgt	gaaggagatt	cagaagcctc	tgctgagctc	3660
aattgagcta	gtggaatgac	cgacgggtgag	atggaagtat	gttttgcggg	tactcgctag	3720
gagaatactg	gtcgtttatc	atgattacaa	atagcttggt	tatgttttta	ttagcattta	3780
cagttgaaca	aggataatta	ctactgaata	ggcagctgaa	actgatgtct	gtaactccag	3840
cctgttattc	cacttgcctg	caggtccttg	catggccaag	tcatacatac	ctgttacggg	3900
gtcgggtgca	cagggctatc	cataccccgg	cccagcctgc	agtagagcag	gcgtcacggc	3960
ctgtagtgcg	ctgcgggaat	cttccaccgg	ttcggatgtg	ggaagtgttg	ttgtcctcgg	4020
ggctaacaca	ttccaacctat	taattgatct	tcaaaacgct	tgcatthtgc	ctatatggcc	4080
ggccttgatc	cttgtatatt	ttcaccatct	gacattttct	gcacaaggcg	tacagaaacc	4140
acacgaggta	aagtttcatg	gccgcttgcc	cactatttga	aacacgacac	acatgttaaa	4200
ctctatcctt	gcattatatt	gtaacatcgc	ctaacatctc	cacgcactat	tcctttgcgt	4260
tccttattca	tcctcaactg	tatgccaacc	aacaatcatc	aaattattat	tgcatgtagt	4320
catcatggat	ttcccaaagc	cgaggcaggt	tagagagacg	agcctgttga	tgtactacct	4380
ggacgtcgtg	ttttctctac	aatgcattac	cccaaacaac	aattgtctgg	gcaagagaga	4440
gtggctgttg	actataactaa	cctctgctcg	gcctacgtac	tatgcaacat	tgtgcctggc	4500
cctcctttat	aaagaatccc	tctcaagccc	ttgcagagcc	gaacaagcgg	tagtatggaa	4560
gagagaaaag	acctactact	acattcctgc	gctccaagag	tctcagaagc	tgttgggtgg	4620
actcgacaag	acttttggtg	tcacaaggct	gaagggggacc	gtcgttgccc	ttgcttgcat	4680
gatccagctc	atcgggtttg	aggtaaagacg	aatccacaac	gctcacaatg	ttcaataccc	4740
gatctataat	tatcatttga	gactaacgca	tttggaacagt	cttcgcactt	aagttagggga	4800
gatttggcgg	ttcacctcct	tgacgccaac	acactcattc	ctgtgttggt	cgaggggttg	4860
tccacagctt	tgcaatcagg	ccctccagcc	acttcaatct	gggtgtgagt	ggatgattcg	4920
gatttgcggc	caactgaaga	tcaaaattcc	ttgagcttcg	aatatccttg	tgctttgaga	4980
ttcttgtcaa	actccctggc	gacaaccggc	atccttatcg	gcatactctg	tggcccatca	5040
gcaccattcg	aagattattg	tcacctctta	gaccagccag	gcctcataca	gatggatgag	5100
gtgctagggg	gcaagaactg	ggccatgctg	actatactcg	aagtgggtta	gctggaccgg	5160
tggaaagcgc	aggagcaaga	gcacaaccgt	ttgagcctaa	agacactcgc	taggcgtgca	5220

atgatgatag	aggacatggt	gacagacgag	ctacaaaagc	tccgggcaag	cgagacactg	5280
cctgatctca	tcaaccatat	ttacgccgcc	tccattatga	catacctgca	tacagtagtt	5340
tcaggactca	atcccaacct	ttcagaggtc	caggatagtg	tgaacgcaac	gattctattg	5400
ttggagagac	tcacagatct	gcaagctgtc	gcgtctgtta	cttggccttt	ggctgtcaca	5460
ggttgcatgg	cctcggaaa	tcataaggac	tttttcagaa	atactctgag	gtcctatgac	5520
gcgacattca	cctcgttaaa	aaagtatgat	ggaactcttg	aggtttttga	agacgcttgg	5580
aacaaaacgag	agatagacag	agagtctcca	atcaggtggg	aggatctgat	ggatcaccat	5640
gggcttccag	tgctcctact	ctaggggttg	tatcatcccc	agacactcgt	gctaccaaca	5700
cacagactgt	cttttagctt	tattttgcct	acgctacctg	attcatgtaa	gttcgggtgt	5760
cacttgccga	cgatacatcc	aggggaagtct	gactagtcag	tgcttatggg	tcgattcctt	5820
ttggcgttat	aaaccggttc	tgtcatgaag	caagatatga	tttcgatgag	agggaaagagc	5880
gaacaactat	tcacatgtaa	cttaaattat	agactttcag	tataaacttt	cgattataag	5940
ccacaccta	tctaagtata	tatatccaat	caattgtacc	aaaagtagtc	tggaatcatg	6000
gttgtaaatc	ggtgctgtgt	tcttccatat	tcttgacatg	atttgacttg	tccggtccgc	6060
gcgacacacg	atggtgatca	taatgaagga	gtggtgattt	tgagtaggaa	aagatattgc	6120
agttccttgt	aaagatcggt	cggaaacgaaa	cccggctgga	gtatgatttg	ttcgtggacc	6180
cgaagtgcaa	aaatgccgga	attaatgaca	ggcattctct	tcagttggct	tgggttgaga	6240
tattggtctg	cgtctgtttg	aaagctgaca	ttggactctt	aacatgcttt	tgccgcgacc	6300
catagtggtg	cgcataaggc	agcgtcgact	cccagatgag	cgaaaacctc	gagccacgaa	6360
acatcagggg	ccatttccgt	tgagtcgatc	aatttagcgg	ctgcgagcat	cgtcgagagt	6420
ttgggataag	tctttgagtg	gacaacagta	atgtgatatg	gtatgatctg	atgtcgtgtt	6480
cgtgttgatg	agaataaatt	gttgagctga	ttcccatcgg	ctctgaccaa	cagttaatat	6540
ctaaattctt	ctactatcta	tgcactatgg	actggggagt	caacgtttgt	cgttctctgg	6600
agagaggcct	aaatgatctt	gaattggtgt	gtaactgaaa	cgtcagtaga	aggcctgaat	6660
tcgcaagcgc	cgaacttccg	gcctacactg	ccactgactt	tgccggctcag	catttagata	6720
gtgggcttca	cagcgggtat	tgtctcttct	gcagcatttc	tacggattta	tccgcttcaa	6780
caacccttcg	tgaaccaatg	atgggtttaca	ttgattggga	ttcggtttta	aactttttgtc	6840
aggttggcag	aggcctaaaa	ctgcgcgtcg	gtgtgtgaga	gaccattgaat	caggcccctg	6900
cattaatgta	ggcattttgc	taccccgcgc	caaagacgca	gaaaagc		6960

```
<210> 2
<211> 380
<212> PRT
<213> Fusarium
```

<400> 2																
Met	Glu	Asn	Phe	Pro	Thr	Glu	Tyr	Phe	Leu	Asn	Thr	Ser	Val	Arg	Leu	
1				5					10					15		
Leu	Glu	Tyr	Ile	Arg	Tyr	Arg	Asp	Ser	Asn	Tyr	Thr	Arg	Glu	Glu	Arg	
			20					25					30			
Ile	Glu	Asn	Leu	His	Tyr	Ala	Tyr	Asn	Lys	Ala	Ala	His	His	Phe	Ala	
		35					40					45				
Gln	Pro	Arg	Gln	Gln	Gln	Leu	Lys	Val	Asp	Pro	Lys	Arg	Leu	Gln		
	50					55				60						
Ala	Ser	Leu	Gln	Thr	Ile	Val	Gly	Met	Val	Val	Tyr	Ser	Trp	Ala	Lys	
65					70				75						80	
Val	Ser	Lys	Glu	Cys	Met	Ala	Asp	Leu	Ser	Ile	His	Tyr	Thr	Tyr	Thr	
				85					90					95		
Leu	Val	Leu	Asp	Asp	Ser	Ser	Asp	Asp	Pro	Tyr	Pro	Ala	Met	Met	Asn	
			100					105					110			
Tyr	Phe	Asn	Asp	Leu	Gln	Ala	Gly	Arg	Glu	Gln	Ala	His	Pro	Trp	Trp	
		115					120					125				
Ala	Leu	Val	Asn	Glu	His	Phe	Pro	Asn	Val	Leu	Arg	His	Phe	Gly	Pro	
		130				135					140					
Phe	Cys	Ser	Leu	Asn	Leu	Ile	Arg	Ser	Thr	Leu	Asp	Phe	Phe	Glu	Gly	
145					150					155				160		
Cys	Trp	Ile	Glu	Gln	Tyr	Asn	Phe	Gly	Gly	Phe	Pro	Gly	Ser	His	Asp	
				165					170					175		
Tyr	Pro	Gln	Phe	Leu	Arg	Arg	Met	Asn	Gly	Leu	Gly	His	Cys	Val	Gly	
			180					185					190			

Ala Ser Leu Trp Pro Lys Glu Gln Phe Asp Glu Arg Gly Leu Phe Leu  
195 200 205  
Glu Ile Thr Ser Ala Ile Ala Gln Met Glu Asn Trp Met Val Trp Val  
210 215 220  
Asn Asp Leu Met Ser Phe Tyr Lys Glu Phe Asp Asp Glu Arg Asp Gln  
225 230 235 240  
Ile Ser Leu Val Lys Asn Tyr Val Val Ser Asp Glu Ile Thr Leu His  
245 250 255  
Glu Ala Leu Glu Lys Leu Thr Gln Asp Thr Leu His Ser Ser Lys Gln  
260 265 270  
Met Val Ala Val Phe Ser Asp Lys Asp Pro Gln Val Met Asp Thr Ile  
275 280 285  
Glu Cys Phe Met His Gly Tyr Val Thr Trp His Leu Cys Asp His Arg  
290 295 300  
Tyr Arg Leu Asn Glu Ile Tyr Glu Lys Val Lys Gly Gln Lys Thr Glu  
305 310 315 320  
Asp Ala Gln Lys Phe Cys Lys Phe Tyr Glu Gln Ala Ala Asn Val Gly  
325 330 335  
Ala Val Ser Pro Ser Glu Trp Ala Tyr Pro Pro Ile Ala Gln Leu Ala  
340 345 350  
Asn Ile Arg Ser Lys Asp Val Lys Asp Val Lys Asp Val Lys Glu Ile  
355 360 365  
Gln Lys Pro Leu Leu Ser Ser Ile Glu Leu Val Glu  
370 375 380

<210> 3  
<211> 20  
<212> DNA  
<213> Fusarium

<400> 3  
ggctgctcat cactttgctc

20

<210> 4  
<211> 20  
<212> DNA  
<213> Fusarium

<400> 4  
tgcataagc actcaatcgt

20

<210> 5  
<211> 377  
<212> PRT  
<213> Fusarium

<400> 5  
Met Glu Asn Phe Pro Thr Glu Tyr Phe Leu Asn Thr Ser Val Arg Leu  
1 5 10 15  
Leu Glu Tyr Ile Arg Tyr Arg Asp Ser Asn Tyr Thr Arg Glu Glu Arg  
20 25 30  
Ile Glu Asn Leu His Tyr Ala Tyr Asn Lys Ala Ala His Phe Ala  
35 40 45  
Gln Pro Arg Gln Gln Gln Leu Leu Lys Val Asp Pro Lys Arg Leu Gln  
50 55 60  
Ala Ser Leu Gln Thr Ile Val Gly Met Val Val Tyr Ser Trp Ala Lys  
65 70 75 80  
Val Ser Lys Glu Cys Met Ala Asp Leu Ser Ile His Tyr Thr Tyr Thr  
85 90 95  
Leu Val Leu Asp Asp Ser Ser Asp Asp Pro Tyr Ala Ala Met Met Asn





[illegible]

42

26

26

31

31

20

20

1

1

Page 6

<400> 16	
cggtatcgaa tgtactcgag	20
<210> 17	
<211> 17	
<212> DNA	
<213> Fusarium	
<400> 17	
cccatggtgt gaacacc	17
<210> 18	
<211> 13	
<212> DNA	
<213> Fusarium	
<400> 18	
gatcgattta aat	13
<210> 19	
<211> 13	
<212> DNA	
<213> Fusarium	
<400> 19	
tcgaatttaa atc	13
<210> 20	
<211> 40	
<212> DNA	
<213> Fusarium	
<400> 20	
cgaatttcat atttaaagtc cgaccagcag acggccctcg	40
<210> 21	
<211> 30	
<212> DNA	
<213> Fusarium	
<400> 21	
gcgatatcat gatctctctg gtactcttcg	30
<210> 22	
<211> 30	
<212> DNA	
<213> Fusarium	
<400> 22	
gcgatatcat cgaccagcag acggccctcg	30
<210> 23	
<211> 32	
<212> DNA	
<213> Fusarium	
<400> 23	
gcgttttaaac atgatctctc tgggtactctt cg	32

<210> 24  
<211> 18  
<212> DNA  
<213> Fusarium

<400> 24  
ggtagcacga gtgtctgg

18